Induction of a physiological dispersion response in bacterial cells in a biofilm

Description

FIELD OF THE INVENTION

The present invention is directed to a method of inducing a physiological dispersion response in bacterial cells in a biofilm.

BACKGROUND OF THE INVENTION

Due to the compact nature of biofilm structures, the presumed reduced physiological state of biofilm bacteria and the protection conferred by biofilm matrix polymers, natural and artificial chemical agents are unable to adequately attack and destroy infectious biofilm populations (Costerton et al., “Bacterial Biofilms in Nature and Disease,” Annu. Rev. Microbiol. 41:435-464 (1987); Hoiby et al., “The Immune Response to Bacterial Biofilms,” In Microbial Biofilms, Lappin-Scott et al., eds., Cambridge: Cambridge University Press (1995)). Increased antibiotic resistance is a general trait associated with biofilm bacteria. When attached, bacteria exhibit a profound resistance, rendering biofilm cells 10-1000 fold less susceptible to various antimicrobial agents than the same bacterium grown in planktonic (free floating) culture. For instance, chlorine (as sodium hypochlorite) an oxidizing biocide considered to be one of the most effective antibacterial agents, has been shown to require a 600 fold increase in concentration to kill biofilm cells of Staphylococcus aureus when compared to planktonic cells of the same species (Luppens et al., “Development of a Standard Test to Assess the Resistance of Staphylococcus aureus Biofilm Cells to Disinfectants,” Appl Environ Microbiol. 68:4194-200 (2002)). Several hypotheses have been advanced to account for the extraordinary resistance of biofilm bacteria to antibiotics including: (i) reduced metabolic and divisional rates exhibited by biofilm bacteria (particularly those deep within the biofilm); (ii) the biofilm EPS matrix may act as an adsorbent or reactant, reducing the amount of agent available to interact with biofilm cells. Additionally, the biofilm structure may physically reduce the penetration of antimicrobial agents by walling off access to regions of the biofilm; (iii) biofilm cells are physiologically distinct from planktonic bacteria, expressing specific protective factors such as multidrug efflux pumps and stress response regulons (Brown et al., “Resistance of Bacterial Biofilms to Antibiotics: A Growth-Rate Related Effect?” J. Antimicrob. Chemotherapy 22:777-783 (1988); Anwar et al., “Establishment of Aging Biofilms: Possible Mechanism of Bacterial Resistance to Antimicrobial Therapy,” Antimicrob. Agents Chemother. 36:1347-1351 (1992); Mah et al., “Mechanisms of Biofilm Resistance to Antimicrobial Agents,” Trends Microbiol. 9:34-39 (2001); Sauer et al., “Pseudomonas aeruginosa Displays Multiple Phenotypes During Development as a Biofilm,” J. Bacteriol. 184:1140-1154 (2002); Stewart, P. S., “Mechanisms of Antibiotic Resistance in Bacterial Biofilms,” Int. J. Med. Microbiol. 292:107-113 (2002); Donlan et al., “Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms,” Clinical Microbiol. Reviews 15:167-193 (2002); Gilbert et al., “The Physiology and Collective Recalcitrance of Microbial Biofilm Communities,” Adv. Microb. Physiol. 46:202-256 (2002); Gilbert et al., “Biofilms In vitro and In vivo: Do Singular Mechanisms Imply Cross-Resistance?” J. Appl. Microbiol. Suppl. 98S-110S (2002)). As detailed molecular studies emerge, it is becoming apparent that each of these factors plays a role in the unusual resistance of biofilms to antimicrobials. Initial treatment is usually effective in killing bacteria only at the margins of biofilm microcolonies. Bacteria deep within these microcolonies are unaffected by the antibiotic and form a nidus for continued dissemination of the infection.

Microbial biofilms in infections and in industrial systems present significant problems due to their recalcitrance to effective treatment.

Detachment is a generalized term used to describe the removal of cells (either individually or in groups) from a biofilm or substratum. Bryers, J. D., “Modeling Biofilm Accumulation,” In: Physiology Models in Microbiology. Bazin et al., eds., Boca Raton, Fla., Vol. 2, pp. 109-144 (1988) categorized four distinct detachment mechanisms by which bacteria detach from a biofilm. These are: abrasion, grazing, erosion, and sloughing. These mechanisms have been described principally from the point of view of the chemical and physical environment acting upon biofilm bacteria. Active detachment as a physiologically regulated event has been hinted at by many authors, but few studies have been performed to demonstrate a biological basis for detachment of bacteria from a biofilm.

One study on the physiological regulation of detachment was carried out by Peyton et al., “Microbial Biofilms and Biofilm Reactors,” Bioprocess Technol. 20:187-231 (1995) on P. aeruginosa. In their work, it was observed that substrate limitation resulted in a decrease in the detachment rate, presumably a result of reducing the growth rate. Allison et al., “Extracellular Products as Mediators of the Formation and Detachment of Pseudomonas fluorescens Biofilms,” FEMS Microbiol. Lett. 167:179-184 (1998) showed that following extended incubation, P. fluorescens biofilms experienced detachment, coincident with a reduction in EPS. In Clostridium thermocellum, the onset of stationary phase has been correlated with increased detachment from the substratum (Lamed et al., “Contact and Cellulolysis in Clostridium thermocellum via Extensive Surface Organelles,” Experientia 42:72-73 (1986)). It has been postulated that starvation may lead to detachment by an unknown mechanism which allows bacteria to search for habitats richer in nutrients (O'Toole et al., “Biofilm Formation as Microbial Development,” Ann. Rev. Microbiol. 54:49-79 (2000)).

The transition from a flowing system to a batch culture system has been observed by many labs to result in biofilm detachment. One lab has observed reproducible detachment of biofilm cells of P. aeruginosa when flow is arrested in a continuous culture system (Davies, D. G., “Regulation of Matrix Polymer in Biofilm Formation and Dispersion,” In Microbial Extracellular Polymeric Substances, pp. 93-112, Wingender et al., eds., Berlin: Springer (1999)).

The release of degradative enzymes has been proposed by others. One such example is found with the gram-positive organism Streptococcus mutans which produces a surface protein releasing enzyme (SPRE), shown to mediate the release of proteins from the cell envelope (Lee et al., “Detachment of Streptococcus mutans Biofilm Cells by an Endogenous Enzymatic Activity,” Infect. Immun. 64:1035-1038 (1996)). Boyd et al., “Role of Alginate Lyase in Cell Detachment of Pseudomonas aeruginosa,” Appl. Environ. Microbiol. 60:2355-2359 (1995) showed that over-expression of alginate lyase causes the degradation of alginate. When a mucoid strain of P. aeruginosa was induced to over-express alginate lyase, cells were more easily removed by gentle rinsing from solid medium.

Cell density dependent regulation may also be responsible for the release of enzymes which can degrade biofilm matrix polymers allowing bacteria to disperse from a biofilm. It has been observed at the Center for Biofilm Engineering at Montana State University, USA (Davies, D. G. and Costerton, J. W.) and in the laboratories of Dr. Lapin-Scott at the University of Exeter, UK, that when certain bacteria (including P. aeruginosa) reach high cell densities in biofilm cell clusters, the bacteria often undergo a detachment event. Mutants of P. aeruginosa which lacked the ability to synthesize the quorum sensing autoinducer 3OC₁₂-HSL, were susceptible to detachment following treatment with mild detergent (Davies et al., “The Involvement of Cell-to-Cell Signals in the Development of a Bacterial Biofilm,” Science 280:295-298 (1998)). Other investigators have demonstrated that homoserine lactones may play a role in detachment. Lynch et al., “Investigation of Quorum Sensing in Aeromonas hydrophila Biofilms Formed on Stainless Steel”, In: Biofilms—The Good, the Bad and the Ugly, Wimpenny et al., eds. Bioline, Cardiff. pp. 209-223 (1999) reported an increase in detachment of Aeromonas hydrophila from biofilms and Puckas et al., “A Quorum Sensing system in the Free-Living Photosynthetic Bacterium Rhodobacter sphaeroides,” J. Bacteria 179:7530-7537 (1997) reported that homoserine lactone production was negatively correlated with cell cluster formation in Rhodobacter sphaeroides.

It has been recognized that P. aeruginosa biofilms do not develop into macroscopic biofilm structures in batch culture flasks (at the glass liquid interface). Yet, when medium is pumped continuously through such a flask, (as in a chemostat) a luxurious biofilm develops completely coating the glass surface. When flow is halted in such a system, the biofilm sloughs after a number of days, generally around 72 hrs (Davies et al., “The Involvement of Cell-to-Cell Signals in the Development of a Bacterial Biofilm,” Science 280:295-298 (1998)). The inability of biofilms to develop in batch culture has been observed for a number of gram negative and gram-positive bacteria as well as mixed cultures of bacteria. This phenomenon demonstrates that there is some aspect of batch growth that is inhibitory to biofilm development.

During the last stage of biofilm development, the protein profile of bacteria matches more closely the protein profile of planktonic cells than it does biofilm bacteria from the previous stage, denoted maturation II (see FIG. 3 of the current application, and Sauer et al., “Pseudomonas aeruginosa Displays Multiple Phenotypes During Development as a Biofilm,” J. Bacteriol. 184:1140-1154 (2002)).

Due to the compact nature of biofilm structures, the presumed reduced physiological state of biofilm bacteria and the protection conferred by biofilm matrix polymers, current natural and artificial chemical agents are unable to adequately attack and destroy infectious biofilm populations (Costerton et al., “Bacterial Biofilms in Nature and Disease,” Annu. Rev. Microbiol. 41:435-464 (1987); Hoiby et al., “The Immune Response to Bacterial Biofilms,” In Microbial Biofilms, Lappin-Scott et al., eds., Cambridge: Cambridge University Press (1995)).

The present invention is directed to overcoming these and other deficiencies in the art.

SUMMARY OF THE INVENTION

One aspect of the present invention is directed to a composition. The composition comprises one or more dispersion inducers having the following formula:

H₃C—(CH₂)_n—CH_m custom character CH_mR,

Another aspect of the present invention relates to a method of treating or preventing a condition mediated by a biofilm in a subject. The method comprises providing a subject having, or susceptible to, a condition mediated by a biofilm produced by a microorganism, whereby the biofilm comprises a matrix and the micro-organism on a surface. Administered to the subject is a dispersion inducer comprising:

H₃C—(CH₂)_n—CH_m custom character CH_mR,

where custom character is a single or double carbon-carbon bond, m is 1 or 2, n is 2 to 15, and R is a carboxylic acid, a salt, an ester, or an amide, where the ester or amide is an isostere or biostere of the carboxylic acid, under conditions effective for the dispersion inducer to selectively act on the microorganism and have a suitable biological response without a required direct effect on the matrix. As a result, the condition mediated by a biofilm in the subject is treated or prevented.

An additional aspect of the present invention relates to a method of treating or inhibiting formation of a biofilm on a surface. This method involves providing a surface having or being susceptible to formation of a biofilm produced by a microorganism, where the biofilm comprises a matrix and the micro-organism on the surface. Administered to the surface is a dispersion inducer comprising:

H₃C—(CH₂)_n—CH_m custom character CH_mR,

where custom character is a single or double carbon-carbon bond, m is 1 or 2, n is 2 to 15, and R is a carboxylic acid, a salt, an ester, or an amide, where the ester or amide is an isostere or biostere of the carboxylic acid, under conditions effective for the dispersion inducer to selectively act on the microorganism and have a suitable biological response without a required direct effect on the matrix. As a result, formation of the biofilm on the surface is treated or inhibited.

Another aspect of the present application relates to a solution comprising:

a dispersion inducer having the following formula:

H₃C—(CH₂)_n—CH_m custom character CH_mR,

where custom character is a single or double carbon-carbon bond, m is 1 or 2, n is 4 to 7, and R is a carboxylic acid, where said inducer is present at a concentration less than 0.5 percent by weight, and where said solution has a pH greater than 5.

A further aspect of the present invention is directed to a composition comprising: a component selected from one or more of the group consisting of biocides, surfactants, antibiotics, antiseptics, detergents, chelating agents, virulence factor inhibitors, gels, polymers, pastes, edible products, and chewable products. In addition, the composition includes a dispersion inducer comprising:

H₃C—(CH₂)_n—CH_m custom character CH_mR,

where custom character is a single or double carbon-carbon bond, m is 1 or 2, n is 4 to 7, and R is a carboxylic acid. The inducer is formulated in a non-salt form.

Another form of the present application is directed to a solution comprising: a cis isomer of 2-decenoic acid, where the solution is selected from the group consisting of a skin cream, a toothpaste, and a mouthwash and where said solution is trans isomer-free.

Another form of the present application is for a method which comprises providing contact lenses and a solution comprising a dispersion inducer at a concentration less than 0.5% by weight, said inducer comprising:

H₃C—(CH₂)_n—CH_m custom character CH_mR,

where custom character is a single or double carbon-carbon bond, m is 1 or 2, n is 4 to 7, and R is a carboxylic acid, a salt, an ester, or an amide, where the ester or amide is an isostere or biostere of the carboxylic acid. The contact lenses are then treated with said solution.

A further form of the present invention is for a method which involves providing a subject with a skin condition and a solution having a pH greater than 5, where the solution comprising a dispersion inducer at a concentration less than 0.5% by weight said inducer comprising:

H₃C—(CH₂)_n—CH_m custom character CH_mR,

Further aspects of the present invention relate to methods of: treating subjects with burns; treating and/or preventing dental plaque, dental caries, gingival disease, and oral infection; cleaning and/or disinfecting contact lenses; treating and/or preventing acne or other biofilm-associated skin infections on the skin of a subject, and treating and/or preventing a chronic biofilm-associated disease in a subject. The methods involve administering the dispersion inducer according to the present invention, under conditions effective to accomplish each respective task. Advantageously, the biofilm dispersion inducer is highly bioactive on the microorganisms within the biofilm, and, therefore, the pharmaceutically acceptable formulation need not be chemically or mechanically active to disrupt the matrix directly. Thus, the composition may have a mild pH and be non-irritating.

The present invention also relates to a composition comprising one or more dispersion inducers and one or more additive components. These additive components are selected from the group consisting of biocides, surfactants, antibiotics, antiseptics, detergents, chelating agents, virulence factor inhibitors, gels, polymers, pastes, edible products, and chewable products. The composition is formulated so that when it is contacted with a biofilm produced by a microorganism, where the biofilm comprises a matrix and microorganism on a surface, the dispersion inducer selectively acts on the microorganism and has a suitable biological response without a required direct effect to disrupt the matrix.

Another aspect of the present invention relates to a method of treating or preventing a condition mediated by a biofilm in a subject. This method involves providing a subject having, or susceptible to, a condition mediated by a biofilm produced by a microorganism, whereby the biofilm comprises a matrix and the micro-organism on a surface. A dispersion inducer is administered to the subject under conditions effective for the dispersion inducer to selectively act on the microorganism and have a suitable biological response without a required direct effect on the matrix, whereby the condition mediated by a biofilm in the subject is treated or prevented.

A further embodiment of the present application is directed to a method of treating or inhibiting formation of a biofilm on a surface. This involves providing a surface having or being susceptible to formation of a biofilm produced by a microorganism, whereby the biofilm comprises a matrix and the micro-organism on the surface. A dispersion inducer is administered to the surface under conditions effective for the dispersion inducer to selectively act on the microorganism and have a suitable biological response without a required direct effect on the matrix, whereby formation of the biofilm on the surface is treated or inhibited.

The present invention addresses the “biofilm problem” by artificially inducing bacteria to undergo physiological process of biofilm dispersion. The ability to induce dispersion will allow the control of biofilms directly and will improve existing treatments with biocides, topical antibiotics, detergents, etc. The examples of situations in which artificial dispersion would be of benefit include improved cleaning of contact lenses and teeth, improved antiseptic activity in the home, in industry, and in the medical community and enhanced cidal activity for existing antibiotic treatments such as with burn patients infected with Pseudomonas aeruginosa.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-B are schematic representations of biofilm treated with an antibiotic and/or a dispersion inducer. As shown in FIG. 1A, following treatment, only the cells on the surface of the biofilm are killed by the antibiotic. FIG. 1B is a schematic representation of a biofilm induced to disperse along with treatment with antibiotic. Dispersed cells are completely killed during the treatment.

FIGS. 2A-C depict the effect of addition of chloroform extracted spent culture medium (CSM) which contains a dispersion inducing compound, to mature biofilms of Pseudomonas aeruginosa. FIG. 2A shows biofilm growing in continuous culture on a glass slide in a flow cell. FIG. 2B shows the same area of biofilm 5 minutes after the addition of the dispersion inducer. FIG. 2C shows complete disaggregation of biofilm following 30 minutes initial treatment with dispersion inducer.

FIG. 3A is a schematic representation of the life cycle of a biofilm. 1, Planktonic bacteria are transported (actively and passively) to the substratum. 2, Cell surface molecules interact with the substratum resulting in reversible surface attachment. 3, Phenotypic changes in the bacterial cell result in cell surface modifications and the production of extracellular polymeric substances, which irreversibly cement the cells to the surface. 4, Physiological changes continue with alterations in metabolism, cell-cell signaling and morphology as biofilm maturation occurs. 5, Cells release degradative enzymes to digest matrix polymer material and alter surface appendages as biofilm detachment occurs. The series of photomicrographs at the bottom of FIG. 3B, show, in order, phase contrast photomicrographs of the five stages of biofilm development by P. aeruginosa grown in continuous culture in a flow-cell and imaged by microscopy. (Sauer et al., “Pseudomonas aeruginosa Displays Multiple Phenotypes During Development as a Biofilm,” J. Bacteriol. 184:1140-1154 (2002), which is hereby incorporated by reference in its entirety).

FIGS. 4A-B are phase contrast photomicrographs of biofilm 20 dispersion induced by cessation of flow. FIG. 4A shows early biofilm development under flowing conditions, while FIG. 4B is the same location after flow is stopped for 72 hrs.

FIG. 5 is a graph showing the effect of chloroform extraction on spent medium dispersion activity. Biofilms were cultured for six days in continuous culture in EPRI medium in biofilm tube reactors (Sauer et al., “Pseudomonas aeruginosa Displays Multiple Phenotypes During Development as a Biofilm,” J. Bacteria 184:1140-1154 (2002), which is hereby incorporated by reference in its entirety) and treated with spent medium (control) and chloroform extracted spent medium (CSM). Cell dispersion was determined as the optical density of culture effluent collected at the end of culture tubes. The error bar represents standard deviation for three replicate experiments.

FIG. 6A shows microcolonies of P. aeruginosa biofilms grown in continuous culture demonstrating native dispersion response. During the dispersion stage of biofilm development, bacteria become motile within cell clusters and exit to the bulk liquid through a breach in the microcolony wall. Each photomicrograph shows a microcolony whose interior has been voided in this manner. The arrow indicates the location of a void. Images taken at 1000× magnification; bar represents 10 μm. FIG. 6B is a transmitted light image, and FIG. 6C is a fluorescent image showing the size dependence of dispersion response. Biofilm microcolonies growing in continuous culture having dimensions of greater than 40 μm diameter×10 μm thickness show dispersion (left 3). Microcolonies below this minimum dimension remain “solid” (right 2 photomicrographs). Fluorescence indicates presence of cells (lacZ reporter on chromosome). All images are the same relative size at 500× magnification; bars represent 40 μm. Arrows indicate void areas within microcolony.

FIGS. 7A-D show treatment of P. aeruginosa mature biofilms with spent medium, CSM and cis-2-decenoic acid. As shown in FIG. 7A, at 30 min, biofilms grown in silicone tubing were exposed to spent medium or fresh medium. Bacteria in effluent were collected continuously for 100 min and cell density determined by OD₆₀₀. As shown in FIG. 7B, biofilm grown in continuous culture in silicone tubing for 4 days and switched either to fresh medium for 1 hr, or CSM for 1 hr. Extruded contents of control tube shows intact biofilm. Extruded contents of CSM-treated biofilm shows dispersion. Photomicrographs show addition of CSM to mature biofilm grown in continuous culture in a microscope-mounted flow cell, as shown in FIG. 7C. Microcolony disaggregation is shown to begin at 7 min. After 30 min exposure, the microcolony had completely disaggregated. Dispersed cells were actively motile (not visible in static image), indicating a change in phenotype compared to cells in intact microcolony (prior to CSM addition). As shown in FIG. 7D, addition of 10 μM cis-2-decenoic acid (cis-DA) to mature biofilm grown in continuous culture in a microscope-mounted flow cell. Microcolony disaggregation is shown to begin at 11 min. Complete microcolony disaggregation is shown within 30 min exposure. Control biofilms treated with carrier fluid were not affected by treatment up to 1 hr.

FIGS. 8A-B show biofilm development in the continuous presence of CSM diluted in modified EPRI to concentration of Spent medium. Average thickness (FIG. 8A) and surface area of biofilms grown in the presence of CSM (FIG. 8B) are significantly less than for untreated biofilms. Grey bars, biofilms treated with CSM. Black bars, biofilms grown in the absence of dispersion inducer. Error bars represent one standard deviation for 20 randomly selected microcolonies

FIG. 9 shows dispersion of different bacterial biofilms by P. aeruginosa CSM using microtiter plate dispersion bioassay. Y-axis indicates number of cells released into the bulk liquid of 16 replicate wells in 3 replicate experiments, following treatment for 1 hr with CSM or carrier control (−), containing sterile medium. Hatched line indicates level of dispersion in carrier control samples. All differences between CSM samples and controls are statistically significant at indicated P-value as determined by Student's T-test.

FIGS. 10A-C show a microtiter plate dispersion bioassay. FIG. 10A shows optical densities of cells released from biofilm-containing microtiter plate wells. White bar, control sample treated with EPRI alone. Grey bar, sample treated with CSM. Black bars represent biofilms treated with C-18 reverse phase HPLC fractions of CSM eluted in an acetonitrile gradient from 2% to 75%. Results are the average of 16 replicate wells, error bars represent one standard deviation. Results from Student's T-test show P<0.001 for CSM and 22-minute HPLC samples. FIG. 10B shows microtiter plate biofilm dispersion bioassay comparing various concentrations of cis-2-decenoic acid to spent medium. Optical densities of cells released from biofilm-containing microtiter plate wells. Negative control wells contained P. aeruginosa treated with 10% ethanol in EPRI. Grey bar represents biofilms treated with spent medium. Black bars represent biofilms treated with increasing concentrations of cis-2-decenoic acid in 10% ethanol. Results are the average of 16 replicate wells, error bars represent one standard deviation. Student's T-test indicated P<0.001 for all cis-2-decenoic acid samples compared to control. FIG. 10C shows the structure of cis-2-decenoic acid.

FIG. 11 shows dispersion of different bacterial biofilms by cis-2-decenoic acid using microtiter plate dispersion bioassay. Y-axis indicates number of cells released into the bulk liquid of 16 replicate wells in 3 replicate experiments, following treatment for 1 hr. with 0.01 μM cis-2-decenoic acid (CDA), or carrier control (−), containing medium+10% ethanol. Hatched line indicates level of dispersion in carrier control samples. All differences between cis-2-decenoic acid treated samples and controls are statistically significant at indicated P-value as determined by Student's T-test.

FIGS. 12A-C show the spectral analysis of P. aeruginosa CSM and cis-2-decenoic acid. FIG. 12A shows product ion mass peaks for the 171 M/Z molecule detected in active HPLC CSM fraction and for synthetic cis-2-decenoic acid. Y-axis indicates intensity; X-axis indicates M/Z in positive ion mode. CSM sample matches peaks from synthetic cis-2-decenoic acid. Note that in mass spectrometry, peak intensity is not a direct indication of concentration. FIG. 12B shows GC-MS spectrum of P. aeruginosa CSM and cis-2-decenoic acid. CSM sample Peak at 15.9 min, indicates solvent carrier. Y-axis indicates intensity; X-axis indicates time in minutes. FIG. 12C shows FT-IR spectrum of P. aeruginosa CSM and cis-2-decenoic acid. Y-axis indicates absorbance; X-axis indicates reciprocal centimeters.

FIG. 13 shows the addition of 10 μM cis-2-decenoic acid (cis-DA) to mature biofilm grown in continuous culture in a microscope-mounted flow cell. Microcolony disaggregation is shown to begin at 11 min. Complete microcolony disaggregation is shown within 15 min exposure. Control biofilms treated with carrier fluid were not affected by treatment up to 1 hr.

DETAILED DESCRIPTION OF THE INVENTION

One aspect of the present invention is directed to a composition. The composition includes one or more dispersion inducers comprising:

H₃C—(CH₂)_n—CH_m custom character CH_mR,

where custom character is a single or double carbon-carbon bond, m is 1 or 2, n is 2 to 15, and R is a carboxylic acid, a salt, an ester, or an amide, where the ester or amide is an isostere or biostere of the carboxylic acid. The composition additionally contains one or more additive components selected from the group consisting of biocides, surfactants, antibiotics, antiseptics, detergents, chelating agents, virulence factor inhibitors, gels, polymers, pastes, edible products, and chewable products. The composition is formulated so that when it is contacted with a biofilm produced by a microorganism, where the biofilm comprises a matrix and microorganism on a surface, the dispersion inducer selectively acts on the microorganism and has a suitable biological response without a required direct effect on the matrix to disperse the biofilm. In achieving this result, the dispersion inducer of the present invention can act in preference directly on the matrix. Alternatively, the dispersion inducer can act on the microorganism which, in turn, acts to disrupt the matrix. This effect may also involve not relying on a direct effect on the matrix. Typically, the biofilm inducer will have no effect on the matrix directly or be present at a concentration where no direct effect on the matrix is evident. On the other hand, the range of effective concentrations suggest a biochemical response mechanism in the microorganisms, wherein the dispersion inducer mimics an intercellular communication composition. The composition acts to induce a dispersion response by the bacteria, which in turn is responsible for release of the bacteria from the biofilm. Additionally, the composition is able to act on bacteria not in a biofilm (planktonic bacteria), inducing these bacteria to mount a physiological response which prevents the formation of a biofilm. Additional components of a composition may be directed to disrupting or removing the matrix from the surface or substrate. For example, the composition may comprise a dentifrice adapted to abrasively remove plaque from teeth.

The R group of the above inducer may be selected from the group consisting of:

embedded image

Alternatively, R can be a homoserine lactone or a furanone group. The composition also includes an additive component such as one or more of biocides, surfactants, antibiotics, antiseptics, detergents, chelating agents, virulence factor inhibitors, gels, polymers, pastes, edible products, or chewable products.

The dispersion inducer of the present invention desirably comprises 7-10 carbon atoms. It is preferred that this inducer be a carboxylic acid (e.g., a monounsaturated fatty acid). It is more preferred that the dispersion inducer comprise:

H₃C—(CH₂)_n—CH custom character CH—COOH

Suitable non-salt forms of this dispersion inducer being the following respective cis- and trans-isomers:

embedded image

Of these, the cis isomer is preferred.

Other suitable alkanoic acids include hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, tetradecanoic acid, pentanoic acid, hexadecanoic acid, heptadecanoic acid, octadecanoic acid, and nonadecanoic acid.

Useful alkenoic acids include 2-hexenoic acid, 2-heptenoic acid, 2-octenoic acid, 2-nonenoic acid, 2-undecenoic acid, 2-dodecenoic acid, 2-tridecenoic acid, 2-tetradecenoic acid, 2-pentadecenoic acid, 2-hexadecenoic acid, 2-heptadecenoic acid, 2-octadecenoic acid, and 2-nonadecenoic acid. These may be cis or trans isomers.

The composition of the present invention can be formulated at a number of pH ranges, to treat different types of bacteria, as follows: 1.5 to 4.5 for acid loving bacteria; 4.5 to 8.0 for acid tolerant bacteria; 6.8 to 7.4 for substantially neutral pH loving bacteria; and 8.0 to 9.8 for alkali tolerant bacteria. An essentially neutral pH is particularly desirable for subjects with acid reflux. The concentration of the dispersion inducer can be 0.01 μM to 30 mM.

The composition can be entirely or substantially (i.e. less than 10 wt %) ethanol free and/or formaldehyde free.

A surface (or substrate) coated with the composition is also encompassed by the present invention.

Another aspect of the present invention relates to a method of treating or preventing a condition mediated by a biofilm in a subject. The method comprises providing a subject having, or susceptible to, a condition mediated by a biofilm produced by a microorganism, whereby the biofilm comprises a matrix and the micro-organism on a surface. Administered to the subject is a dispersion inducer comprises:

H₃C—(CH₂)_n—CH_m custom character CH_mR,

where custom character is a single or double carbon-carbon bond, m is 1 or 2, n is 2 to 15, and R is a carboxylic acid, a salt, an ester, or an amide, where the ester or amide is an isostere or biostere of the carboxylic acid, under conditions effective for the dispersion inducer to selectively act on the microorganism and have a suitable biological response without a required direct effect on the matrix. As a result, the condition mediated by a biofilm in the subject is treated or prevented. The method of dispersing the biofilm may further include administering to the biofilm, in conjunction with administering the dispersion inducer, an antimicrobial treatment. The treatment can be the administration of biocides (e.g., hydrogen peroxide), surfactants, antibiotics, antiseptics, detergents, chelating agents, virulence factor inhibitors, gels, polymers, pastes, edible products, chewable products, ultrasonic treatment, radiation treatment, thermal treatment, and/or mechanical treatment.

where custom character is a single or double carbon-carbon bond, m is 1 or 2, n is 2 to 15, and R is a carboxylic acid, a salt, an ester, or an amide, where the ester or amide is an isostere or biostere of the carboxylic acid, under conditions effective for the dispersion inducer to selectively act on the microorganism and have a suitable biological response without a required direct effect on the matrix. As a result, formation of the biofilm on the surface is treated or inhibited.

In one embodiment, the surface to be treated includes indwelling medical devices, such as catheters, respirators, and ventilators. In addition, the surface can be in implanted medical devices, including stents, artificial valves, joints, pins, bone implants, sutures, staples, pacemakers, and other temporary or permanent devices. The dispersion inducer of the present invention can also be included in surgical glue. In another embodiment, the surface to be treated includes drains, tubs, kitchen appliances, countertops, shower curtains, grout, toilets, industrial food and beverage production facilities, flooring, and food processing equipment. In a further embodiment, the surface to be treated is a heat exchanger surface or a filter surface. Thus, treatment provides a means for reducing the degree of bio fouling of the heat exchanger or filter. In a final embodiment, the surface to be treated is a marine structure which includes boats, piers, oil platforms, water intake ports, sieves, and viewing ports. The surface can alternatively be associated with a system for water treatment and/or distribution (e.g., a system for drinking water treatment and/or distributing, a system for pool and spa water treatment, a system for treatment and/or distribution of water in manufacturing operations, and a system for dental water treatment and/or distribution). The surface can also be associated with a system for petroleum drilling, storage, separation, refining and/or distribution (e.g., a petroleum separation train, a petroleum container, petroleum distributing pipes, and petroleum drilling equipment). The dispersion inducer can also be included in formulations directed at reducing or eliminating biofilm deposits or bio fouling in porous medium, such as with oil and gas bearing geological formations. The treatment may be accomplished by applying a coating, such as paint, to the surface.

The method of inhibiting formation of a biofilm on a surface may further involve administering to the surface, in conjunction with administering the dispersion inducer, an antimicrobial treatment. The treatment can be administration of biocides, surfactants, antibiotics, antiseptics, disinfectants, medicines, detergents, chelating agents, virulence factor inhibitors, ultrasonic treatment, radiation treatment, thermal treatment, and mechanical treatment. In one embodiment, the dispersion inducer and the antimicrobial treatment are administered simultaneously. In another embodiment, the dispersion inducer and antimicrobial treatment are administered separately.

The dispersion inducer can be impregnated in a surface in order to inhibit formation of a biofilm on the surface. Alternatively, the dispersion inducer can be in a copolymer or a gel coating over the surface.

The present invention also relates to a method of treating subjects with burns. The method involves administering the dispersion inducer according to the present invention, under conditions effective to treat burns in the subject. A specific application of the invention provides a topical dressing for burn patients comprising dispersion inducing molecules or their natural or synthetic analogs to prevent the development of infectious biofilms or to disperse the cells of existing infectious biofilms.

The present invention further relates to a method of treating and/or preventing dental plaque, dental carries, gingival disease, periodontal disease, and oral infection in a subject. The method involves treating the oral cavity of the subject with the dispersion inducer according to the present invention. Treating can be carried out with a dentifrice, mouthwash, dental floss, gum, strip, toothpaste, a toothbrush containing the dispersion inducer, and other preparations containing the dispersion inducer. The composition may also contain other compounds known in the dental arts that are typically added to dental compositions. For example, the dispersion inducer composition may also include fluoride, desensitizing agents, anti-tartar agents, antibacterial agents, remineralization agents, whitening agents, and anti-caries agents.

The amount of dispersion inducer present will vary dependent on the dental composition that contains the dispersion inducer. It has been found that the dispersion inducer is active over a wide range of concentrations against oral bacteria. For instance, the dispersion inducer may be present in an amount ranging from 0.1 nM to 10 mM. However, lower and higher concentrations may be used depending on the dental composition, the other components present in the dispersion inducer composition, and various other factors appreciated by those of skill in the art. The known properties of the dispersion inducer, such as its fatty acid characteristics and its hydrophobicity, will assist a skilled artisan in determining how much of the dispersion inducer should be used, determining how the compound will chemically interact with other components, and providing other useful information about the compound.

Specific dental applications and dental compositions are contemplated in this invention. In this regard, the invention relates to a toothbrush containing a dispersion inducer composition. Toothbrushes, as is well known in the art, contain a plurality of bristles and a solid support on which the bristles are mounted, where the solid support includes a brush head having a plurality of tuft holes that receive the bristles. Variations and modifications of the basic toothbrush are well known in the art. See, for example, U.S. Pat. No. 7,251,849, herein incorporated by reference in its entirety.

The dispersion inducer of this invention has a chemical formula as set forth above. Additional components that may be included in the dispersion inducer compositions are also set forth above. The dispersion inducer composition may be incorporated in the various parts of the toothbrush by means known in the art. For instance, the dispersion inducer composition may be contained in the tuft holes of the toothbrush. See U.S. Pat. No. 5,141,290, herein incorporated by reference in its entirety, for an example of how a composition can be contained within the tuft holes of a toothbrush. Alternatively, the dispersion inducer composition may be coated or embedded in the bristles of the toothbrush.

Other parts of the toothbrush may also be coating or embedded with the dispersion inducer composition, including any parts of the toothbrush that supplement the bristles and are designed to be contacted with the oral cavity. For example, it is common for toothbrushes to contain rubber paddles, tongue cleaners, or other pieces extended from the head for the purposes of being contacted with the tooth, tongue, gums, or other areas of the oral cavity. These parts may be embedded with the dispersion inducer composition and, optionally, a surfactant, biocide, and/or other additive discussed above.

To assist in controlling the release of the dispersion inducer from the toothbrush, the dispersion inducer composition may contain an agent that interacts with the dispersion inducer to assist in the controlled release. The agent may interact with the dispersion inducer in a manner that the release is either accelerated or prolonged, depending on the desired use. The level of controlled release can also depend on how easily or difficult the dispersion inducer adheres to the portion of the toothbrush that it is applied to. In a preferred embodiment, the dispersion inducer is slowly released from the toothbrush over repeated brushings. Agents that enable the slow release of an active ingredient are well known to those of skill in the art.

The controlled release may also be effectuated by encapsulating the dispersion inducer in an encapsulated system that allows a controlled release. In this embodiment, the dispersion inducer composition is preferably in the form of a plurality of small microspheres that encapsulate the dispersion inducer. The microspheres can have an outer coating of dissolvable material that enables the dispersion inducer to slowly release over repeated brushings. Suitable microspheres include those disclosed in U.S. Pat. No. 5,061,106, herein incorporated by reference in its entirety.

This invention also relates to a toothpaste composition that contains (a) fluoride and/or a remineralization agent; (b) an orally-accepted vehicle; and (c) a dispersion inducer composition. The dispersion inducer of this invention has a chemical formula as set forth above. Additional components that may be included in the dispersion inducer compositions are also set forth above. Often, toothpastes also contain sodium lauryl sulfate or other sulfates.

Fluoride in its various forms is a common active ingredient in toothpaste to prevent cavities and promote the formation of dental enamel and bones. Any fluoride source, such as fluoride salts may be used in the toothpaste of this invention. Preferably, the fluoride is sodium fluoride (NaF) or sodium monofluorophosphate (Na₂PO₃F). Typically, the amount of fluoride present in the toothpaste ranges from 100 to 5000 parts per million fluoride ion, preferably 1000 to 1100 parts per million.

In certain instances, it is preferable to replace or supplement the fluoride with a remineralization agent. Remineralization, in the context of dental usage, generally refers to treating the teeth so as to prevent dental caries, or decrease their chance of occurring, and otherwise enhance the teeth so that they can return to their original, healthy state. While fluoride can be considered a remineralization agent, other agents often take the place of fluoride or supplement fluoride to provide the toothpaste with a stronger cleansing or remineralization properties. Common remineralization agents are calcium salts, such as calcium phosphate, calcium sulfate, anhydrous calcium sulfate, calcium sulfate hemihydrate, calcium sulfate dihydrate, calcium malate, calcium tartrate, calcium malonate, and calcium succinate. Hydroxyapitate nanocrystals and zinc compounds have also been shown to be effective remineralization agents.

The orally-accepted vehicle may be any vehicle known in the art that can be used to deliver the fluoride and/or remineralization agent, and dispersion inducer to the teeth of a patient. The orally-accepted vehicle may also be glycerin, propylene glycol, polyethylene glycol, triglyceride, diglyceride, mineral oil, organic oils, essential oils, fatty vegetable oils, and combinations thereof. Often these vehicles are used in combination with water or a water-based solvent.

The toothpaste composition may contain other components of toothpastes well known in the art. For instance, the toothpaste composition may contain baking soda, enzymes, vitamins, herbs, calcium compounds such as calcium sodium phosphosilicate, coloring agents, and/or flavoring agents. Desensitizing agents may also be added. As known in the art, desensitizing agents can reduce sensitivity in teeth by treating sensitivities caused by demineralization or suppressing the sensitivity symptoms by desensitizing the nerves. The composition may also contain an antibacterial or an antiplaque agent. Antibacterial agents are preferable included in the composition to prevent gingivitis, periodontitis, and other oral diseases. Suitable antibacterial agents include triclosan, zinc chloride, chlorhexidine, benzthonium chloride, and cetyl pyridinium chloride.

This invention also relates to an oral composition for treating and/or preventing dental plaque, gingival diseases, periodontal diseases, and/or oral infection. The oral composition contains an orally-accepted vehicle and a dispersion inducer composition. The dispersion inducer of this invention has a chemical formula as set forth above. Additional components that may be included in the dispersion inducer compositions are also set forth above.

The oral composition can be various compositions in the field of dental hygiene known to those in the art. For instance, the oral composition may be a mouthwash, breath spray, dentifrice, tooth powder, whitening strips, or prophylaxis paste. As is well known in the art, mouthwashes are commonly used to help remove mucous and food particles in the oral cavity or throat. Mouthwashes typically contain antiseptic and/or anti-plaque components to kill the bacterial plaque that causes caries, gingivitis, and bad breath. They can also contain anti-cavity components, such as fluoride, to protect against tooth decay. Suitable mouthwash components may be found in U.S. Pat. No. 5,968,480, herein incorporated by reference in its entirety.

Likewise, the same or similar antiseptic, anti-plaque, and anti-cavity components can be used in breath sprays, dentifrices, including gel dentifrices, tooth powders, whitening strips, and prophylaxis pastes. Suitable breath spray compositions are disclosed in U.S. Pat. No. 7,297,327; suitable tooth powder compositions, such as those used in tooth bleaching compositions, are disclosed in U.S. Pat. No. 5,989,526; suitable whitening strips are disclosed in U.S. Pat. No. 6,514,483; and suitable dentifrices and prophylaxis paste compositions, including dental abrasives, are disclosed in U.S. Pat. No. 5,939,051, all of which are herein incorporated by reference in their entirety.

The ingredients of orally-accepted vehicle are similar to those discussed above. However, the orally-accepted vehicle will vary depending on the desired consistency and desired end product of the oral composition. For instance, a mouthwash is in a liquid form, so liquid carriers, typically carriers having a high percentage of water, should be used. On the other hand, a gel dentifrice should be in the form of a gel and would utilize gelling agents or other carriers that enable the final product to be in the form of a gel. The orally-accepted vehicle should have properties that both allow the dispersion inducer composition to be delivered while also providing the final product with the desired consistency.

The oral composition may also be in the form of chewing gum, a breath strip, a lozenge, or a breath mint. Chewing gum is typically a combination of a water-insoluble phase, or gum base, and a water-soluble phase of sweeteners, flavoring and/or food coloring. Other components may also be added to the gum, including breath-freshening additives such as zinc and phosphate salts, teeth-whitening additives such as silica, and plaque-reducing additives to moderate dental plaque. Suitable gum compositions may be found in U.S. Pat. Nos. 6,416,744 and 6,592,849, both of which are herein incorporated by reference in their entirety.

Breath strips are similar to chewing gum, except that the strips are designed to dissolve in the mouth, often absorbed through the tongue. The strips can deliver bioactive ingredients to freshen the mouth as well functional bioactive ingredients, such as vitamins, minerals, supplements, pharmaceuticals, and vaccines.

Lozenges and breath mints are typically discoid-shaped solids that contain a therapeutic agent in a flavored base. The base may be a hard sugar candy, glycerinated gelatin or combination of sugar with sufficient mucilage to give the composition requisite form. The dispersion inducer may represent the therapeutic agent, or it may be added in addition to therapeutic agents known in the art. Suitable lozenge and breath mint compositions are disclosed in U.S. Pat. No. 7,025,950, herein incorporated by reference in its entirety.

The oral composition may also be in the form of a cleaning preparation for a dental apparatus that is placed in the oral cavity. Dental apparatuses such as dentures, dental dams, and certain types of orthodontic braces are placed in the oral cavity for a period of time, and then periodically removed for cleaning. The cleaning composition used to clean the dental apparatuses should function in its customary manner of cleaning the apparatus, but may also contain therapeutic agents that can assist in treating or preventing dental plaque, gingival diseases, periodontal diseases, and oral infection when the dental apparatuses are in contact with the oral cavity. Cleaning compositions such as effervescent cleansers made with alkaline mixtures containing a chlorine compounds and the like are known in the art. Suitable cleaning compositions for dental apparatuses are disclosed in U.S. Pat. No. 3,936,385, herein incorporated by reference in its entirety. The dispersion inducer may be added to the cleaning compositions in a manner than enables it to coat the dental apparatus upon contact. After the dental apparatus has been introduced into the oral cavity, the dispersion inducer can interact with the teeth and other elements of the oral cavity in a therapeutically effective manner, i.e. to prevent dental plaque, gingival diseases, periodontal diseases, and/or oral infection.

This invention also relates to an article for oral use comprising a dental article and a dispersion inducer. The dispersion inducer has the chemical formula set forth above, and is coated on, encapsulated in, or impregnated in the dental article. Additional components that may be included in the dispersion inducer compositions are also set forth above.

Various dental articles known in the art may be used in this embodiment of the invention. In one embodiment, the dental article is a dental floss. Any fiber known in the art may be used in the dental floss. Suitable fibers include polyamides (such as nylon), polyesters, polypropylenes, polytetrafluoroethylenes, cellulose, and cotton. Nylon and polytetrafluoroethylene fibers are the most common fibers used in dental floss and represent preferred fibers. Suitable dental flosses are disclosed in U.S. Pat. Nos. 6,270,890 and 6,289,904, both of which are herein incorporated by reference in their entirety. The dispersion inducer composition may be impregnated into the fiber, coated on the fiber, or otherwise incorporated into the dental floss.

The dental floss may be coated or impregnated with a wax or other hydrophobic substance for ease of use during the flossing process. Suitable waxes include microcrystalline waxes, beeswax, paraffin waxes, carnauba waxes, and polyethylene waxes. The dispersion inducer composition may be coated onto the dental floss as part of the wax layer, as a second or additional layer in conjunction with the wax layer, or applied to the fiber as discussed above.

The dental article may be a toothpick that is impregnated with or coated with the dispersion inducer composition. Toothpicks may be made from natural products, such as wood, or artificial components, including various plastics. Suitable toothpicks are disclosed in U.S. Pat. No. 7,264,005, herein incorporated by reference in its entirety.

The dental article may also be a dental appliance such as a dental aspirator, bite block, dental dam, tongue stabilizer, tongue deflector, or any other piece of dental equipment that a dentist or dental assistant may use in the mouth of a patient. A discussion of dental appliances may be found in U.S. Pat. Nos. 4,865,545 and 5,152,686, both of which are herein incorporated by reference. The portion of the dental appliance that comes into contact with the oral cavity of a patient may be coated with the dispersion inducer composition.

The dental article may also be a dental construct, such as veneers, crowns, inlays, onlays, or bridges that are placed on the teeth. Dental constructs are typically made of metal alloys, porcelain, ceramic, amalgam, acrylate polymers, or a combination of these materials. Suitable dental constructs are disclosed in U.S. Pat. No. 7,229,286, herein incorporated by reference in its entirety. The dispersion inducer composition may be embedded in the composition used to make the dental construct. Alternatively, the dispersion inducer composition may be coated on the dental construct after it has been prepared.

This invention also relates to an aqueous composition applied to the oral cavity with the use of a dental article, comprising water and a dispersion inducer composition. Various dental articles are attached to or designed to be used with a water line so that water can be distributed through the dental article, and then routed from the dental article to the oral cavity of a subject. Suitable dental articles include dental water lines, dental water picks, and the like.

While tap water or purified water may be used in these types of dental devices, the water source may also be supplemented with additives so that the water delivers the additives to the oral cavity of the subject when used with the dental article. In this case, the additive supplemented to the water is a dispersion inducer composition.

Dental water lines and dental water picks are known in the art and commonly used by dentists and dental assistants. A discussion of different types of dental water lines and their different applications may be found in U.S. Pat. No. 5,785,523, herein incorporated by reference in its entirety. Suitable water picks are disclosed in U.S. Pat. No. 4,257,433, herein incorporated by reference in its entirety.

The present invention also relates to a method of cleaning and/or disinfecting contact lenses. The method involves treating contact lenses with a cleaning and/or disinfecting solution containing the dispersion inducer according to the present invention. The contact lens may be treated in this manner while being stored in solution or while being used in vivo. Alternatively, the dispersion inducer can be used in eye drops.

The present invention further relates to a method of treating and/or preventing acne or other biofilm-associated skin infections on the skin of a subject. The method involves treating the skin of the subject with the dispersion inducer according to the present invention under conditions effective to treat and/or prevent the acne or biofilm-associated skin infections. The dispersion inducer may be present in an ointment, cream, liniment, salves, shaving lotion, or aftershave. It may also be present in a powder, cosmetic, ointment, cream, liquid, soap, gel, cosmetic applicator, and/or solid, woven or non-woven material intended to contact or be proximate with the skin.

The present invention also relates to a method of treating and/or preventing a chronic biofilm-associated disease in a subject. The method involves administering to the subject the dispersion inducer according to the present invention under conditions effective to treat and/or prevent the chronic biofilm-associated disease. The chronic biofilm-associated diseases to be treated and/or prevented include, but are not limited to, middle ear infections, osteomyelitis, prostatitis, colitis, vaginitis, urethritis, arterial plaques, sinovial infections, infections along tissue fascia, respiratory tract infections (e.g., infections associated with lung infections of cystic fibrosis patients, pneumonia, pleurisy, pericardial infections), genito-urinary infections, and gastric or duodenal ulcer infections. For gastric or duodenal ulcers caused by Helicobacter pylori, the dispersion inducer will need to function at a pH of below 5.5. The dispersion inducer may be administered in combination with an antimicrobial agent, such as biocides, surfactants, antibiotics, antiseptics, detergents, chelating agents, or virulence factor inhibitors. In the case of gastric therapies, acid reducing therapies, such as antacids, proton pump inhibitors, antihistamines, and the like may also be employed.

Another aspect of the present application relates to a solution comprising:

a dispersion inducer comprises:

H₃C—(CH₂)_n—CH_m custom character CH_mR,

A further aspect of the present invention is directed to a composition comprising: a component selected from one or more of the group consisting of biocides, surfactants, antibiotics, antiseptics, detergents, chelating agents, virulence factor inhibitors, gels, polymers, pastes, edible products, and chewable products. In addition, the composition includes a dispersion inducer comprises:

H₃C—(CH₂)_n—CH_m custom character CH_mR,

where custom character is a single or double carbon-carbon bond, m is 1 or 2, n is 4 to 7, and R is a carboxylic acid. The inducer is formulated in a non-salt form.

The present invention is also directed to a solution which includes a cis isomer of 2-decenoic acid, where the solution is selected from the group consisting of a skin cream, a toothpaste, and a mouthwash and where the solution is substantially free of the trans isomer of 2-decenoic acid. As interpreted herein, this solution is substantially free of a trans isomer if a reduction in trans isomer (without change in cis-isomer) concentration does not increase bioactivity. It is more preferred that there be a molar ratio of cis to trans of at least 2.

Another form of the present application is for a method which comprises providing contact lenses and a solution comprising a dispersion inducer at a concentration less than 0.5% by weight, said inducer comprises:

H₃C—(CH₂)_n—CH_m custom character CH_mR,

A further form of the present invention is for a method which involves providing a subject with a skin condition and a solution having a pH greater than 5, where the solution comprising a dispersion inducer at a concentration less than 0.5% by weight said inducer comprises:

H₃C—(CH₂)_n—CH_m custom character CH_mR,

EXAMPLES

The following examples are provided to illustrate embodiments of the present invention but are by no means intended to limit its scope.

Example 1

Bacterial Strains and Media

The microorganisms used in this study included Pseudomonas aeruginosa PAO1 from B. H. Holloway, Escherichia coli (ATCC 10798), Proteus mirabilis (ATCC 25933), Klebsiella pneumoniae (ATCC 10273), Staphylococcus aureus (ATCC 12602), Streptococcus pyogenes (ATCC 19615), Bacillus subtilis (ATCC 6633), and Candida albicans (ATCC 20260) and a mixed undefined culture collected on R2A plates via airborne contamination. Except where indicated, all experiments were performed in modified EPRI medium, containing 0.005% ammonium nitrate, 0.00019% KH₂PO₄, 0.00063% K₂HPO₄(pH 7.0), and 0.001% Hutner salts (Cohen-Bazire et al., J. Cell. Comp. Physiol. 49:35 (1957), which is hereby incorporated by reference in its entirety), supplemented with 0.2% glucose. C. albicans was grown in modified EPRI medium supplemented with 0.2% glucose and 0.1% peptone. K. pneumoniae, P. mirabilis, S. aureus, and B. subtilis were grown in modified EPRI medium supplemented with 0.1% peptone. S. pyogenes was grown in 10% Brain Heart Infusion broth.

Example 2

Preparation of P. aeruginosa Spent Medium

To prepare cell-free spent culture medium, 6 mL of an overnight culture of P. aeruginosa PAO1 grown in modified EPRI medium at 30° C. were inoculated into four liters of modified EPRI medium and incubated for 10 days at room temperature with continuous stirring. Bacterial cells were sedimented by centrifugation (Sorvall RC 5B Plus Centrifuge, GSA Rotor; Thermo Electron Co., Ashville, N.C.) at 13,000×g for 15 minutes at 4° C. The supernatant was removed and filtered under vacuum through a 0.45 μm Millipore Type HA filter (Millipore. Co., Billerica, Mass.) and subsequently, through a 0.2 μm, Acrodisc 32 mm syringe filter (PALL Co., East Hills, N.Y.). Spent medium was stored at 4° C.

Example 3

Preparation of CSM

The organic components of spent medium were extracted by adding 80 mL of chloroform to 250 mL of filtered spent medium in a separatory funnel. The chloroform fraction was removed after a separation time of 1 hr. Chloroform was evaporated at 40° C. using a Rotavapor R-3000 rotary evaporator (Biichi Laboratories, Flawil, Switzerland) and the remaining organic material was re-suspended in 6 mL of filtered nanopure water and evaporated to dryness using a Speed-Vac evaporator system (Savant Instruments, Inc., Hicksville, N.Y.) or lyophilized. These samples were then resuspended in culture medium or purified water. The final product is referred to as Chloroform extracted Spent Medium (CSM). Except where indicated, CSM was used in experiments at a final chloroform extracted organic carbon concentration 125 fold greater than found in spent medium.

Example 4

HPLC Fractionation of CSM

CSM was fractionated by High Performance Liquid Chromatography (HPLC) (Varian Prostar model 320, Varian Inc., Palo Alto, Calif.) using a C18 Microsorb-mv reverse phase column (Varian Inc.) dimensions 250×4.6 mm. The column was loaded with 100 μL of CSM and eluted in an acetonitrile/water gradient (2-75%) with a flow rate of 1 mL/min for 29 minutes. Samples were collected every minute, starting at 2 minutes. HPLC fractions were pooled and concentrated in a Speed Vac concentrator (Savant Instruments, Inc., Hicksville, N.Y.) and resuspended in 0.5 mL of modified EPRI medium or purified water. The active HPLC fraction was found to elute from the column in 70% acetonitrile/30% water. The active fraction of each HPLC separation was determined by microtiter plate dispersion bioassay.

Example 5

Microtiter Plate Dispersion Bioassay

Microtiter plate dispersion bioassays were used to test various preparations for their ability to exogenously induce biofilm dispersion. Biofilms were grown on the inside surface of microtiter plate wells using a semi-batch culture method in which the medium within each well was replaced periodically to reduce the accumulation of native dispersion inducing factors. Biofilms grown in this manner were treated with dispersion inducer or sterile medium to release cells into the bulk liquid and evaluate dispersed cell number by measuring optical density. Briefly, sterile polystyrene 96 well plates were etched with acetone for 10 seconds to create a rough surface for the attachment of microbial cells. After drying for 24 hours, plates were inoculated with 150 μL/well of overnight culture containing the test organism, previously diluted 1:20 in growth medium and incubated at 30° C. with shaking at 200 rpm. Medium in the wells was replaced every 24 hours for 5 days and every 12 hours on day 6 and day 7. Medium was then replaced after 7 hours. Dispersion induction was tested by adding 150 μL growth medium containing dispersion inducer for 1 hr at 30° C. or sterile medium as a control. Medium containing dispersed cells was then transferred by pipet to a non-etched microtiter plate and the optical density (OD₅₇₀) was determined (ELx808 Absorbance Microplate Reader; BioTek Instruments, Inc., Winooski, Vt.). Treatments consisted of spent medium, CSM, cis-2-decenoic acid, trans-decenoic acid, decanoic acid and DSF at various concentrations. Ethanol (10%) was used as a carrier for fatty acid inducer samples and was determined to have no influence on dispersion. Results from use of this method are meaningful in making comparisons of different treatments and to determine whether dispersion activity is statistically significant. Note: Microtiter plate dispersion bioassays were not suitable for determining absolute magnitude of an induced dispersion response because in a semi-batch system, control and test samples are susceptible to natural dispersion against which the activity of exogenous induction is measured. All efficiency studies were performed using biofilm tube reactor or flow-cell continuous culture systems and were based on both total cell counts and viable cell counts.

Example 6

Dispersion Bioassays in Biofilm Tube Reactors

P. aeruginosa PAO1 biofilm cultures were grown in tube reactors as described previously by Sauer et al. (K. Sauer, et al., J. Bacteriol. 184:1140 (2002), which is hereby incorporated by reference in its entirety). A continuous once-through tube reactor system was configured using 8 silicone reactor tubes (81.5 cm length×14 mm ID), connected to an 8-roller head peristaltic pump and medium reservoir, via additional silicone tubing. Medium was pumped through the tubing to a closed effluent medium reservoir. The assembled system was sterilized by autoclaving prior to inoculation. The silicone tubes were inoculated by syringe injection through a septum 1 cm upstream from each reactor tube, with 2 mL of overnight cultures of P. aeruginosa (containing approximately 1×10⁸CFU/mL). Bacterial cells were allowed to attach (static incubation) to the tubing for 1 hour, after which the flow was started at an elution rate of 10.8 mL/hr. Treatments were carried out following 96 hours of P. aeruginosa PAO1 biofilm cultures. The treatments were performed under continuous and static conditions.

Under continuous treatment (FIG. 17A) the influent medium was changed from fresh medium in the test lines to spent medium amended with 2% glucose, adjusted to neutrality and aerated overnight prior to addition. Control lines were switched to new lines containing fresh modified EPRI medium. Samples were collected for one minute intervals starting at time=0 min, and assayed for optical density. Spent medium was added at time=30 min. Samples were collected in test tubes on ice and were subsequently homogenized for 30 sec at 5000 rpm with a Tissue Tearor Model 985370 (Biospec Products, Inc.) to ensure separation of cells. Cell density was determined by optical density at 600 nm with an Ultrospec 3000 spectrophotometer (Amersham Pharmacia Biotech, Inc.).

Under conditions of static treatment, dispersion inducer was added by syringe injection through the inoculation port, 2 cm upstream from the beginning of the tube reactor, displacing the reactor volume with medium containing inducer. Spent medium was added directly. CSM or synthetic dispersion inducer (e.g.: cis-2-decenoic acid) was prepared in modified EPRI and added. After one hour of exposure under non-flowing conditions, an 81.5 cm length of each silicone tube reactor was cut out, the liquid fraction (containing released biofilm cells) was collected in test tubes on ice and the biofilm fraction was collected by rolling the tube on the lab bench with a metal rod to extrude the cells remaining in the lumen of the tube (K. Sauer, et al., J. Bacteriol. 184:1140 (2002), which is hereby incorporated by reference in its entirety). Samples were collected on ice, and homogenized as above. Cells numbers were determined by spread plate method on Standard Plate Count agar medium (Difco, Detroit, Mich.) or by optical density at OD₆₀₀adjusted to cell number by calibration to a standard curve for cell number as determined microscopically by total cell count. Dispersion efficacy was calculated using either optical density or viability measurements:

$Dispersion Efficacy = \frac{Cells from Bulk Liquid \times 100}{Cells from Bulk Liquid + Cells from Biofilm}$

Example 7

Microscopic Analysis

A continuous-culture once-through flow cell was configured to observe the growth and development of biofilms attached to a glass substratum. The flow cell was constructed of aluminum containing a chamber 1.0 mm by 1.4 cm by 4.0 cm capped with a glass cover slip. Sterile modified EPRI medium was pumped from a 10-liter vessel through silicone tubing to the flow cell using a Masterflex 8-roller-head peristaltic pump at a flow rate of 0.13 mL/min. Flow through the chamber was laminar, with a Reynolds number of 0.17, having a fluid residence time of 4.3 min. Medium leaving the flow cell was discharged to an effluent reservoir via silicone tubing. The entire system was closed to the outside environment but maintained in equilibrium with atmospheric pressure by a 0.2-μm-pore-size gas-permeable filter fitted to each vessel. Log-phase P. aeruginosa (approximately 10⁸CFU/mL) were inoculated as a 3.0 mL slug dose through a septum 4 cm upstream from the flow cell under flowing conditions. Cells attached to the inner surface of the glass cover slip were viewed by transmitted light or epi-UV illumination using an Olympus BX60 microscope and a 100× magnification A100PL objective lens or a 50× magnification ULWD MSPlan long working distance Olympus objective lens. All images were captured using a Magnafire cooled three-chip charge-coupled device (CCD) camera (Optronics Inc., Galena, Calif.) and stored as separate digital files for subsequent retrieval and analysis P. aeruginosa were grown in the flow cell for up to 12 days. Previous work by applicant has shown P. aeruginosa to develop steady-state biofilms following a continuous culture period of 7 to 9 days. Steady state is defined by no change in effluent cell counts (CFU) resulting from detached biofilm cells; in steady state, growth of the biofilm is balanced by the loss of cells through dispersion or detachment. Individual cell clusters were examined during the course of each experiment and assigned grid coordinates, which were reexamined periodically during the course of the experiments. Size measurements were taken of random cell clusters by locating the cluster nearest to a randomly selected microscope stage coordinate. Each cell cluster was measured to determine its height by focusing from the substratum through to the apex of the cluster, and its width by measurement at the base of the cell cluster using a stage micrometer. Cell clusters were defined as cells embedded within an exopolysaccharide matrix attached to the substratum and lacking motility; void areas within cell clusters were determined by the observation of free-swimming bacteria within a space inside a cell cluster.

Example 8

Inhibition of Biofilm Development

A flow cell was used to culture bacteria on the surface of a glass substratum (described above). Biofilms of P. aeruginosa were grown at room temperature over a period of 99 hours in the presence and absence of CSM (diluted 1:125 to match the concentration of the chloroform extracted organic material found in spent medium) in modified EPRI medium. During the course of the experiment, the total cell coverage of the bacteria on the surface and average biofilm thickness were determined by counting 20 microscope fields using a 50×ULWD MSPlan objective lens for each time point. Using the image analysis software, ImagePro Plus, the total area of cells per cm²was determined at 72 hours and 99 hours. Thickness was determined by measuring the average maximum height of 20 random cell clusters at 72 hours and 99 hours of growth. Control samples were grown and tested in the presence of modified EPRI medium with no added CSM. Results from these experiments showed that surface area coverage of the growing biofilm was significantly reduced when biofilms were grown in the presence of CSM compared to biofilms grown in EPRI medium alone. The addition of CSM also caused a significant reduction in the average biofilm cell cluster thickness after 99 hours growth, compared to samples not treated with CSM (FIG. 18).

Example 9

Spectral Analysis of P. aeruginosa CSM and Cis-2-Decenoic Acid

All CSM samples prepared in purified water were lyophilized and resuspended in appropriate carriers for each spectroscopic analysis. CSM controls in all experiments consisted of CSM HPLC products that did not induce dispersion as determined by microtiter plate dispersion bioassay, and carrier solution not containing CSM.

Example 10

Mass Spectroscopy

Samples were resuspended in carrier solution (50% water, 50% methanol and 0.01% formic acid). Mass spectroscopy was performed using a high-performance, hybrid quadrupole time-of-flight mass spectrometer—QSTAR® XL Hybrid LC/MS/MS System (Applied Bio systems, Foster City, Calif., USA)—in positive ion mode, at room temperature, with an IonSpray source for API 150EX™, API 3000™ and QSTAR® Systems (Applied Biosystems). Data were analyzed using Analyst QS version 1.1.

Example 11

Nuclear Magnetic Resonance (NMR)

Samples of CSM and cis-2-decenoic acid were resuspended in 1 mL of deuterated acetonitrile and inserted into a thin walled NMR sample tube (VWR). Analyzes was performed in a 300 MHz Proton NMR-Bruker AC 300 (Bruker Daltonics Inc., Vilarica, Mass., USA). Spectra were accumulated for 24 hours.

Example 12

Gas Chromatography-Mass Spectroscopy (GC-MS)

Samples of CSM and concentrations of cis-2-decenoic acid from 0.01 mg/mL-10 mg/mL were resuspended in 2 mL of acetonitrile. A 3 step-sequential hexane extraction was performed to remove soluble organic sample material. Hexane was evaporated to dryness in a water bath (55-70° C.). Puridine (250 μL) was subsequently added to solubilize samples for injection into GC. Spectra were obtained with a Shimadzu QP5050A GC-MS system, using helium as a carrier as and a Restek (Columbia, Md.) XTI-5 GC column (30 m, 0.25 mm i.d., 0.25 μm film thickness) with a 1 mL/min flow rate. All analyses incorporated splitless injection and electron impact ionization. The interface temperature between the GC and the MS was maintained at 310° C. Data were analyzed using the program Lab Solutions, GCMS solution version 1.2.

Example 13

Infrared Spectroscopy (IR)

Samples of CSM and cis-2-decenoic acid were weighed before and after lyophilization to determine the amount of KBr to add to each sample. KBr was added at 10 times the sample mass and mixed using a mortar and pestle. The resulting powder was formed into a pellet using a Carver 4350 Manual Pellet Press (Carver Inc., Wabash, Ind., USA). Pressure was applied at 10 Tons for 10 min. IR spectra were obtained using a Bruker Equinox 55 FT-IR spectrometer at room temperature in the range of 3500 cm⁻¹to 400 cm⁻¹at a resolution of 1 cm⁻¹. The final spectra represent the mean of 128 scans. Each sample was measured in triplicate.

Example 14

Biofilm Bacteria are Resistant to Antibiotics

FIG. 1A illustrates schematically how biofilm bacteria are resistant to the addition of antibiotics, with similar resistance shown for biocides and other antimicrobial treatments. FIG. 1B illustrates that if a dispersion inducer is added in addition to antibiotic, the dispersed bacteria lose their resistance and become susceptible to the antibiotic.

Example 15

Effect of Dispersion Inducing Compounds

FIG. 2 shows an actual biofilm sample treated with the dispersion inducing compound according to the present invention, derived from cultures of Pseudomonas aeruginosa. In this experiment, a once-through flow-cell was used to culture P. aeruginosa over a period of six days prior to testing with added CSM.

The flow cell was constructed of anodized aluminum, containing a chamber 1.0 mm by 1.4 cm by 4.0 cm capped with a glass cover slip. Sterile EPRI medium was pumped from a 2-liter vessel through silicone tubing to the flow cell using a Masterflex 8-roller-head peristaltic pump at a flow rate of 0.13 ml/min. Flow through the chamber was laminar, with a Reynolds number of 0.17, having a fluid residence time of 4.3 min. Medium leaving the flow cell was discharged to an effluent reservoir via silicone tubing. The entire system was closed to the outside environment but maintained in equilibrium with atmospheric pressure by a 0.2-μm-pore-size gas-permeable filter fitted to each vessel. Log-phase P. aeruginosa (approximately 10⁸CFU/ml) were inoculated as a 3.0-ml slug dose through a septum 4 cm upstream from the flow cell under flowing conditions. Cells attached to the inner surface of the glass cover slip were viewed by transmitted light using an Olympus BX60 microscope and a 50× magnification ULWD MSPlan long working distance Olympus objective lens. All images were captured using a Magnafire cooled three-chip charge-coupled device (CCD) camera (Optronics Inc., Galena, Calif.) and stored as separate digital files for subsequent retrieval and analysis. Following development of a mature biofilm within the flow-cell, medium-flow was stopped and 3 mL of filtered CSM in sterile EPRI medium was added to the flow-cell. Transmitted light images of a single location within the flow-cell were taken before and during treatment with CSM. FIG. 2 shows images taken from such an experiment 1 min prior to addition of CSM, 5 min after addition of CSM, and 30 min after addition of CSM. Control samples were also run in the same manner as the test samples with the exception that CSM was not included with the 6 mL of added EPRI medium. Results from the control samples showed no change in biofilm cell numbers or biofilm architecture, with no dispersion evident.

Example 16

Biofilm Bacteria Undergo a Phenotypic Switch

During the course of normal biofilm development, biofilm bacteria undergo a phenotypic switch at the end of maturation II stage (FIG. 3) in which their physiology changes from a predominantly biofilm form to a predominantly planktonic form. Microscopic observations of biofilms during the dispersion phase demonstrated that bacteria within cell clusters become motile (maturation stage P. aeruginosa are non-motile), while the bacteria around the edges of the clusters remain fixed. The region of the cell cluster within which bacteria can swim/twitch grows in volume from a (usually) central location and eventually a breach is made in the cluster wall. The bacteria are able to swim through this breach and enter the bulk liquid phase leaving behind a void within the cell cluster.

Continued study of the dispersion response has revealed that cell clusters transition through episodes of growth and dispersion; the same cell cluster often enduring many such cycles. Multiple dispersion and regrowth events generally lead to the development of cell clusters with patterns analogous to growth rings which can indicate the number of times that dispersion has occurred. Often cell clusters will detach from the substratum completely during a dispersion event (Stoodley et al., “Growth and Detachment of Cell Clusters from Mature Mixed-species Biofilms,” Appl. Environ. Microbiol. 67:5608-5613 (2001), which is hereby incorporated by reference in its entirety). This effect is thought to be due to weakening of attachment structures at the base of the cell cluster allowing fluid sheer to detach the cluster.

Example 17

Cell Detachment after Medium Stagnation

FIG. 4 depicts a time series of phase contrast photomicrographs showing the detachment of cells after medium stagnation of 72 hours. Flow-cell were inoculated with P. aeruginosa PAO1 and cultured for a period of three days, according to the method described in Example 3, above. The choice of three days for culture of these biofilms was based upon the observation that under continuous flow, cell clusters within a biofilm of P. aeruginosa were observed to undergo spontaneous dispersion events following 9 days of incubation. After 72 days of growth under continuous flow, medium flow was stopped and images of the cell clusters were recorded every two hours for a period of 96 hours. After 72 hours of medium stagnation, the cell clusters within the flow-cell were observed to dis-aggregate, with cells entering the bulk liquid medium as planktonic bacteria (FIG. 4). These experiments demonstrated that cessation of flow induced dispersion of biofilms. response. In these experiments, dispersion occurred not simply within the cell clusters, but throughout all clusters in the biofilm. Only those cells which were directly attached to the substratum were not observed to swim into the bulk liquid, as illustrated in FIG. 4.

Example 18

Development of Chloroform Extraction Method

Various growth and extraction procedures were tested to develop a reliable method of extracting the active fraction of spent culture medium having dispersion inducing activity. Chloroform was chosen as the extraction solvent of choice due to its compatibility with HPLC fractionation procedures, because it resulted in a narrow range of extractable organic compounds (as determined by mass spectrometry) and because it could recover bioactive amounts of the dispersion inducing agent. The method currently used for chloroform extraction of spent medium follows: Bacterial cultures of P. aeruginosa PAO1 were grown in 4 liters of EPRI medium (containing: sodium lactate 0.05 g/l, sodium succinate 0.05 g/l, ammonium nitrate 50.381 g/l, KH₂PO₄0.19 g/l, K₂HPO₄0.63 g/l, Hutner Salts metals solution 1 ml, and glucose, 2.0 g/l) in a batch culture vessel for six days at room temperature with continuous stirring. Following growth, bacteria were removed from the culture medium by centrifugation at 10,000×g for 20 min, followed by filtration of spent medium through a 0.22 μm pore size filter. In batches, 250 ml of filtered spent medium were mixed with 80 ml of chloroform in a reparatory funnel. The chloroform fraction was removed after a separation time of 10 min. The chloroform samples were then evaporated to dryness at 70° C. using a rotavapor R-3000 (Biichi Laboratories, Flawil, Switzerland) and re-suspended in 6 mL of filtered nanopure water or EPRI medium. The final product, resulting from the chloroform extraction procedure is referred to here as concentrated spent medium or CSM. FIG. 15 shows the results of comparing the effect of CSM and Spent Medium on continuous culture biofilms grown in biofilm tube reactors. CSM and Spent medium were prepared as described previously from cultures of P. aeruginosa PAO1 grown at 22° C. for 9 days in EPRI medium supplemented with 2.0 gram per Liter of glucose. Biofilms of P. aeruginosa PAO1 were cultured for six days at 22° C. in biofilm tube reactors consisting of 32 cm silicone dioxide Masterflex size 14 tubing. At the end of six days, 6 mL of CSM, Spent Medium or Sterile EPRI medium, each supplemented with 2.0 gram per Liter glucose, was added to the tubes. The effluent from the tubes was collected and pooled for each treatment over a period of 20 minutes. Pooled sampled were assayed for optical density at 570 nm to determine relative cell numbers dispersed from each treatment. Each experiment was performed with five replicates. Results from these experiments demonstrated that chloroform extracted spent culture medium, CSM showed a greater activity in dispersing biofilms of P. aeruginosa compared to spent medium.

Applicant observed that P. aeruginosa PAO1 will disperse from a continuous culture biofilm grown on a glass substratum in a flow-cell reactor after medium flow had been stopped for several hours. This observation has led to the hypothesis that biofilm dispersion may result from the accumulation of an extracellular messenger which acts as an inducer of biofilm disaggregation. This hypothesis is supported by observations that biofilms of P. aeruginosa will not form in batch culture flasks, but will form on the walls of a chemostat, indicating that accumulation of a signal for dispersion may prevent biofilm development. Furthermore, when grown in continuous culture, microcolonies of P. aeruginosa will form hollow voids at their center when they attain a minimum diameter of 40 microns and thickness of 10 microns (FIG. 6). The microcolony size within which these voids form, however, is dependent on the fluid flow rate. When flow in a biofilm reactor was increased, the diameter and thickness at which microcolony void formation occurred also increased, indicating a relationship between dispersion induction and transport. These observations hinted that an extracellular substance produced by P. aeruginosa was responsible for inducing biofilm dispersion.

If P. aeruginosa produces an extracellular dispersion-inducing compound, applicant postulated that the addition of cell-free spent culture medium to mature P. aeruginosa biofilms should cause the release of cells into the bulk liquid medium. These bacteria should be detectable as an increase in the number of cells recovered in the reactor effluent. FIG. 7A illustrates results from a representative experiment in which biofilms were treated for 70 minutes under continuous flow with cell-free spent medium in which P. aeruginosa had been grown in suspension for 24 hours; fresh medium was added to control biofilms. Prior to addition, spent medium was aerated, supplemented with glucose and its pH adjusted to neutrality, to ensure that starvation, oxygen depletion or a change in pH was not responsible for the release of bacteria. A large spike in the effluent cell number was detectable compared to control lines within 20 minutes of the addition of the spent medium, indicating the release of biofilm bacteria into the effluent of cultures treated with spent medium. A small spike of released cells was also detectable in control samples, likely representing a response to the physical or mechanical effects associated with switching lines to a fresh medium reservoir.

To purify the active dispersion inducing fraction of spent medium, cell-fee stationary-phase batch cultures of P. aeruginosa were extracted using chloroform, followed by rotory evaporation of the chloroform and re-suspension of the organic fraction in fresh medium or buffer solution (resulting in a 125-fold increase in the chloroform-soluble organic fraction). This preparation is referred to as CSM. To test the dispersion-inducing activity of CSM, P. aeruginosa biofilms were grown in continuous culture in silicone tubing and exposed the biofilms for one hour to medium amended with CSM. The extruded contents of the tube reactors showed a largely intact biofilm in the control line treated with fresh medium (FIG. 7B), while the contents of the tubes treated with CSM showed the biofilm to have completely disaggregated (FIG. 7C). Studies of 4-day old biofilms grown in continuous culture in silicone tubing revealed that treatment with CSM-containing medium for one hr was effective in releasing an average 87.4% (±1.4%) of biofilm cells as determined by colony forming units released into the effluent. Spent medium was shown to have an average dispersion efficacy of 32.4% (±5.5%).

Microscopy was used to evaluate the effect of CSM on biofilm microcolonies grown for six days in continuous culture on the glass substratum of a flow-cell mounted to a microscope (K. Sauer et al., J. Bacteriol. 184:1140 (2002), which is hereby incorporated by reference in its entirety). Prior to the addition of CSM, a well-developed microcolony was observed to contain cells that were stationary and showed no sign of motility (FIG. 7D). Following 7 minutes of contact with CSM-containing medium, cells within the microcolony began to twitch and display active motility (FIG. 7E). After 30 minutes, the microcolony had become completely disaggregated and cells were observed to swim freely through the medium (FIG. 7F). When compared to natural dispersion, exogenously induced dispersion was observed to progress from the outside of the microcolony towards the interior and, instead of creating a central void, resulted in complete disaggregation of the microcolony.

When added continuously to flow cells, CSM adjusted to the concentration of spent medium, showed a significant inhibition of biofilm development over a period of 99 hr, demonstrating a reduction in both biofilm average thickness and surface area coverage (FIG. 8). Exogenous dispersion induction of pre-formed biofilms by CSM was measurable at all time points from day 1 (beginning of biofilm microcolony formation) through day 6, after which natural dispersion began to occur. Activity of CSM was shown to persist up to 6 months with no significant reduction when stored under refrigeration. Extraction of spent medium by ethyl acetate (to recover acyl-homoserine lactones) did not result in a preparation with dispersion activity.

Having demonstrated dispersion induction against mature and developing biofilms formed by P. aeruginosa, the ability of CSM to induce dispersion in biofilm cultures of E. coli, E. coli mixed with P. aeruginosa, an undefined mixed bacterial biofilm derived from airborne contaminants, and against biofilms formed by Klebsiella pneumoniae, Proteus mirabilis, Streptococcus pyogenes, Bacillus subtilis, Staphylococcus aureus, and Candida albicans was next tested. CSM was shown to stimulate significant dispersion compared to controls in all samples tested. Results from these experiments are summarized in FIG. 9. The ability of P. aeruginosa dispersion inducer to activate dispersion in different species of bacteria and in yeast indicates that it possesses cross-phylum and cross-kingdom activity.

Having established the role of CSM as an inducer of biofilm dispersion, the active molecule or molecules present in CSM was identified. This began by assaying the dispersion activity of multiple fractions of CSM separated by Isocratic gradient in acetonitrile and water using C-18 reverse phase high performance liquid chromatography (HPLC). Eluted HPLC fractions (collected at one minute intervals) were desiccated in a Speedvac to remove residual acetonitrile and re-suspended in purified water and tested by microtiter plate dispersion bioassay to determine dispersion activity. FIG. 10A shows the results of CSM fractionation biofilm dispersion assays. The results indicated that the HPLC fraction of CSM showing the highest activity eluted at 22 min, an acetonitrile/water ratio of 70%/30%.

Mass spectrometry of the active HPLC CSM fraction showed a consistent molecular peak with low ionization activity at 171 M/Z (mw=170). This peak was present in all samples showing dispersion activity and missing from all samples lacking dispersion activity. This peak was also shown to be missing from all carrier liquids and solvents used in preparing CSM (including fresh culture medium). Mass spectroscopy-product ion analysis of the 170 mw peak, solubility analysis, H¹- and C¹³nuclear magnetic resonance (NMR) spectroscopy and infrared (IR) spectroscopy have demonstrated that the 170 mw molecule was a mono-unsaturated C₁₀-fatty acid, with a double bond located at the number 2 carbon; 2-decenoic acid.

In order to confirm that the 170-mw molecule (M/Z=171) from the 22-minute CSM HPLC fraction was identical to 2-decenoic acid, the original molecule was fragmented in the mass spec to generate product ion peaks. The product ions from the active CSM fraction and 2-decenoic acid were analyzed by quadrapole ms/ms to evaluate cleavage differences between these two molecules. FIG. 12A, shows that the 171 M/Z CSM sample had identity with 2-decenoic acid. When analyzed by GC-MS, unfractionated CSM displayed a single major peak with a retention time of 7.6 min identical to that of 2-decenoic acid FIG. 12B. Infrared spectroscopy confirmed that the cis isomer of 2-decenoic acid was the organic compound isolated from CSM, FIG. 12C.

Following this identification, mono-unsaturated fatty acid molecules of various molecular weights were synthesized and tested these for dispersion activity. DSF, which was shown to disrupt cell flocs of X. campestris was shown not to promote dispersion of P. aeruginosa. The compounds having the highest activity were two isomers of 2-decenoic acid. The trans isomer (trans-2-decenoic acid) was shown by microtiter plate dispersion bioassay to have activity only at millimolar concentrations, typically not low enough to qualify as a cell-cell signaling molecule. FIG. 10B shows the dispersion activity of increasing concentrations of cis-2-decenoic acid against biofilm cultures of P. aeruginosa grown in microtiter plates. These results demonstrated that the cis isomer (cis-2-decenoic acid) was active over a concentration range of 1.0 nanomolar to 10 millimolar, showing greater dispersion activity at 1.0 nanomolar than un-concentrated spent culture medium (i.e.: higher than the naturally occurring inducer). Microscopy revealed that the activity of cis-2-decenoic acid as a dispersion inducer was similar to CSM activity, completely disrupting a biofilm microcolony as shown in FIG. 13. The activity of cis-2-decenoic acid was also tested against E. coli, S. pneumonia, P. mirabilis, S. pyogenes, B. subtilis, S. aureus, and C. albicans biofilm cultures, resulting in similar results to those obtained for CSM (FIG. 11).

This study has shown that a small messenger fatty acid molecule, cis-2-decenoic acid, is produced by P. aeruginosa in batch and biofilm culture. This molecule has been demonstrated to induce a dispersion response in biofilms formed by P. aeruginosa and a range of gram-negative and gram-positive bacteria and in yeast. The dispersion response is a mechanism to escape starvation conditions within a population, allowing fixed cells the opportunity to migrate to a more favorable environment and thin out the population that remains, allowing cells to obtain increased nutrients. When biofilm microcolonies are small, the inducer, which accumulates in the extracellular matrix is removed by diffusive and advective transport. This removal is not possible in batch systems. When cell clusters attain a dimension where the inducer is not adequately washed out from the interior (the rate of diffusion being exceeded by the rate of production), the inducer is able to attain a concentration necessary for activation of the dispersion response, releasing cells from the biofilm. The discovery of a cell-to-cell signaling molecule responsible for biofilm dispersion allows the exogenous induction of the transition of biofilm bacteria to a planktonic state. Use of this dispersion inducer is likely to result in enhanced treatment options in combating biofilm-related infections and in the control of microbial bio fouling.

Although preferred embodiments have been depicted and described in detail herein, it will be apparent to those skilled in the relevant art that various modifications, additions, substitutions, and the like can be made without departing from the spirit of the invention and these are therefore considered to be within the scope of the invention as defined in the claims which follow.

Claims

1. A medical device or dressing, comprising: cis-2-decenoic acid at a concentration of 0.001 μM to 30 μM; anda support configured to release the cis-2-decenoic acid over a length of time.
2. The medical device or dressing of claim 1, wherein the cis-2-decenoic acid is at a concentration of 1 μM to 30 μM.
3. The medical device or dressing according to claim 1, wherein the support comprises cotton.
4. The medical device or dressing according to claim 1, wherein the support comprises a polymer selected from the group consisting of a polyamide, a polyester, a polypropylene, a polytetrafluoroethylene, a copolymer, and cellulose.
5. The medical device or dressing according to claim 1, wherein the support comprises a gel.
6. The medical device or dressing of claim 1, wherein the medical device or dressing is selected from the group consisting of: an indwelling medical device, a catheter; a respirator, a ventilator; a stent; an artificial valve; a joint; a pin; a bone implant, a suture; a staple; and a pacemaker.
7. The medical device or dressing of claim 5, wherein the gel is provided as a coating on a fiber.
8. The medical device or dressing of claim 1, wherein the medical device or dressing is a topical dressing.
9. The medical device or dressing of claim 1, wherein the medical device or dressing is non-bacteriocidal.
10. The medical device or dressing of claim 1, wherein the support is a provided as a coating.
11. A coating for a medical device or dressing, comprising: a polymer or a gel formulated to coat a medical device or dressing, containing cis-2-decenoic acid in a concentration of 0.001 μM to 30 μM,the polymer or gel being configured to prolong a release of the cis-2-decenoic acid with respect to an absence of the polymer or gel, to induce a biological dispersion induction response of a biofilm containing a microorganism exposed to the cis-2-decenoic acid.
12. A biofilm disperser for a medical device or dressing, comprising: cis-2-decenoic acid in a concentration of 0.001 μM to 30 μM; anda gel or polymer configured to release the cis-2-decenoic acid over a length of time.
13. The biofilm disperser according to claim 12, wherein the the gel or polymer comprises a gel.
14. The biofilm disperser according to claim 12, further comprising a biocide.
15. The biofilm disperser according to claim 12, wherein the medical device is selected from the group consisting of a catheter, a ventilator, and a respirator.
16. The biofilm disperser according to claim 12, wherein the medical device comprises a bone implant.
17. The biofilm disperser according to claim 12, further comprising at least one of a biocide and an antibiotic.
18. The medical device or dressing according to claim 1, wherein the medical device or dressing comprises an implantable medical device.
19. The medical device or dressing according to claim 1, wherein the medical device or dressing comprises a suture or surgical staple.
20. The coating for a medical device or dressing according to claim 11, wherein the medical device or dressing is selected from the group consisting of: an indwelling medical device, a catheter; a respirator, a ventilator; a stent; an artificial valve; a joint; a pin; a bone implant, a suture; a staple; and a pacemaker.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 13/945,207, filed Jul. 18, 2013, now U.S. Pat. No. 10,654,140, issued May 19, 2020, which is a divisional of U.S. patent application Ser. No. 12/152,347, filed May 14, 2008, now U.S. Pat. No. 8,513,305, issued Aug. 20, 2013, which claims the benefit of U.S. Provisional Patent Application Ser. Nos. 60/917,791, filed May 14, 2007, and 61/018,639, filed Jan. 2, 2008, which are hereby incorporated by reference in their entirety.

STATEMENT OF GOVERNMENT SUPPORT

This invention was made with government support under grant numbers NSF MCB-0321672 and NIH R15AI055521-01 awarded by NIH and NSF. The government has certain rights in this invention.

US Referenced Citations (1707)

Number	Name	Date	Kind
4097604	Thiele	Jun 1978	A
4214006	Thiele	Jul 1980	A
4215144	Thiele	Jul 1980	A
4224307	Thiele et al.	Sep 1980	A
4442125	Thiele	Apr 1984	A
4976874	Gannon et al.	Dec 1990	A
4978685	Gannon et al.	Dec 1990	A
5428101	Urano et al.	Jun 1995	A
5645841	Hill et al.	Jul 1997	A
5753180	Burger	May 1998	A
5798117	New et al.	Aug 1998	A
6086921	Domenico	Jul 2000	A
6106854	Belfer et al.	Aug 2000	A
6207149	Fuglsang et al.	Mar 2001	B1
6241994	Lee et al.	Jun 2001	B1
6248371	Domenico	Jun 2001	B1
6348187	Pan et al.	Feb 2002	B1
6455031	Davies et al.	Sep 2002	B1
6641739	Dresty, Jr. et al.	Nov 2003	B2
6692757	Day et al.	Feb 2004	B1
6696047	Scott et al.	Feb 2004	B2
6793900	Morck et al.	Sep 2004	B1
6830745	Budny et al.	Dec 2004	B1
6887270	Miller et al.	May 2005	B2
6908912	Rioux et al.	Jun 2005	B2
6936447	Pearson et al.	Aug 2005	B1
6991810	Grundy et al.	Jan 2006	B1
7018642	Degenhardt et al.	Mar 2006	B2
7025986	Brown et al.	Apr 2006	B2
7052614	Barak	May 2006	B2
7087661	Alberte et al.	Aug 2006	B1
7094394	Davies et al.	Aug 2006	B2
7144992	Madhyastha	Dec 2006	B2
7147888	Brown et al.	Dec 2006	B2
7151139	Tiller et al.	Dec 2006	B2
7189329	Barak	Mar 2007	B2
7189351	Levin et al.	Mar 2007	B2
7201925	Gillis	Apr 2007	B2
7217425	Serhan et al.	May 2007	B2
7255881	Gillis et al.	Aug 2007	B2
7314857	Madhyastha	Jan 2008	B2
7399742	DiMauro et al.	Jul 2008	B2
7402722	Hill et al.	Jul 2008	B2
7419607	Downs	Sep 2008	B2
7427416	Gillis et al.	Sep 2008	B2
7446089	Singh et al.	Nov 2008	B2
7450228	Maier et al.	Nov 2008	B2
7452345	Darouiche et al.	Nov 2008	B2
7498051	Man et al.	Mar 2009	B2
7504123	Man et al.	Mar 2009	B2
7534368	Martin	May 2009	B2
7556807	Cvitkovitch et al.	Jul 2009	B2
7592025	Dodds et al.	Sep 2009	B2
7601731	Raad	Oct 2009	B2
7612045	Eldridge	Nov 2009	B2
7628929	Barak	Dec 2009	B2
7691418	Rossel	Apr 2010	B2
7713955	Whiteford et al.	May 2010	B2
7744555	DiMauro et al.	Jun 2010	B2
7760353	Maier et al.	Jul 2010	B2
7781166	Yu et al.	Aug 2010	B2
7790947	Hill et al.	Sep 2010	B2
7794698	Bukshpan et al.	Sep 2010	B2
7795000	Podtburg et al.	Sep 2010	B2
7820193	Hunter et al.	Oct 2010	B2
7829305	Kolari et al.	Nov 2010	B2
7838532	Surber et al.	Nov 2010	B2
7863029	Jaffe	Jan 2011	B2
7887641	Man et al.	Feb 2011	B2
7897631	Melander et al.	Mar 2011	B2
7906544	Melander et al.	Mar 2011	B2
7923425	Held	Apr 2011	B2
7927496	Barak	Apr 2011	B2
7959943	Hissong et al.	Jun 2011	B2
7976873	Myntti et al.	Jul 2011	B2
7993390	Miller et al.	Aug 2011	B2
7993675	Oliver et al.	Aug 2011	B2
7998919	Rong et al.	Aug 2011	B2
8021610	Code	Sep 2011	B2
8067402	Whiteford et al.	Nov 2011	B2
8067403	Whiteford et al.	Nov 2011	B2
8071540	Montelaro et al.	Dec 2011	B2
8076117	Trampuz et al.	Dec 2011	B2
8105520	Miller et al.	Jan 2012	B2
8128976	Man et al.	Mar 2012	B2
8133501	Li et al.	Mar 2012	B2
8142764	Demuth et al.	Mar 2012	B2
8153119	Collins et al.	Apr 2012	B2
8153410	Jaffe	Apr 2012	B2
8153412	Chang et al.	Apr 2012	B2
8162924	Boyden et al.	Apr 2012	B2
8168072	Barak	May 2012	B2
8173673	Bringmann et al.	May 2012	B2
8206740	Chang et al.	Jun 2012	B2
8211361	Sun et al.	Jul 2012	B2
8216173	Dacey, Jr. et al.	Jul 2012	B2
8221480	Boyden et al.	Jul 2012	B2
8227017	Leander et al.	Jul 2012	B2
8231686	Mangiardi	Jul 2012	B2
8236545	Cascao-Pereira et al.	Aug 2012	B2
8246691	Mangiardi	Aug 2012	B2
8246758	Man et al.	Aug 2012	B2
8252550	Otto et al.	Aug 2012	B2
8256233	Boyden et al.	Sep 2012	B2
8257749	Code	Sep 2012	B2
8257827	Shi et al.	Sep 2012	B1
8267883	DiMauro et al.	Sep 2012	B2
8268381	Whiteford et al.	Sep 2012	B2
8273104	Cohen	Sep 2012	B2
8278340	Melander et al.	Oct 2012	B2
8282593	Dacey, Jr. et al.	Oct 2012	B2
8282967	Schoenfisch et al.	Oct 2012	B2
8283135	Doyle et al.	Oct 2012	B2
8298799	Bornscheuer et al.	Oct 2012	B2
8309590	Reid	Nov 2012	B2
8318180	Shirtliff et al.	Nov 2012	B2
8329758	Ali et al.	Dec 2012	B2
8343086	Dacey, Jr. et al.	Jan 2013	B2
8343911	Singh et al.	Jan 2013	B2
8349368	Gordon et al.	Jan 2013	B2
8357696	Surber et al.	Jan 2013	B2
8366652	Dacey, Jr. et al.	Feb 2013	B2
8367713	Melander et al.	Feb 2013	B2
8367716	Karaolis	Feb 2013	B2
8367823	Sun et al.	Feb 2013	B2
8377455	Ceri et al.	Feb 2013	B2
8383101	Olmstead	Feb 2013	B2
8383582	Oh et al.	Feb 2013	B2
8389021	Baker	Mar 2013	B2
8389679	Eckert et al.	Mar 2013	B2
8394405	Chang et al.	Mar 2013	B2
8394406	Chang et al.	Mar 2013	B2
8398705	Mangiardi	Mar 2013	B2
8399235	Frank et al.	Mar 2013	B2
8399649	Yu et al.	Mar 2013	B2
8409376	Boyden et al.	Apr 2013	B2
8414356	Boyden et al.	Apr 2013	B2
8414517	Dacey, Jr. et al.	Apr 2013	B2
8415159	Ward et al.	Apr 2013	B2
8420699	Dubow	Apr 2013	B1
8425880	Lyczak et al.	Apr 2013	B1
8431151	Mather et al.	Apr 2013	B2
8444858	Barak	May 2013	B2
8454566	Van Antwerp	Jun 2013	B2
8460229	Dacey, Jr. et al.	Jun 2013	B2
8460916	Cascao-Pereira et al.	Jun 2013	B2
8461106	Cohen et al.	Jun 2013	B2
8470364	Chang et al.	Jun 2013	B2
8476319	Scholz et al.	Jul 2013	B2
8476425	Lai et al.	Jul 2013	B1
8481138	Miller et al.	Jul 2013	B2
8485861	Boyden et al.	Jul 2013	B2
8486428	Sun et al.	Jul 2013	B2
8501969	Meijler et al.	Aug 2013	B2
8507244	Shaw et al.	Aug 2013	B2
8513305	Davies	Aug 2013	B2
8518031	Boyden et al.	Aug 2013	B2
8524734	Surber et al.	Sep 2013	B2
8524735	Surber et al.	Sep 2013	B2
8545806	Boyden et al.	Oct 2013	B2
8545836	Kaul et al.	Oct 2013	B2
8545855	Boyden et al.	Oct 2013	B2
8545856	Boyden et al.	Oct 2013	B2
8545857	Boyden et al.	Oct 2013	B2
8545951	Yahiaoui et al.	Oct 2013	B2
8546121	Aehle et al.	Oct 2013	B2
8546423	Surber et al.	Oct 2013	B2
8551505	Boyden et al.	Oct 2013	B2
8551506	Boyden et al.	Oct 2013	B2
8552147	Zlotkin	Oct 2013	B2
8552208	Lee et al.	Oct 2013	B2
8557551	Lam et al.	Oct 2013	B2
8563012	Boyden et al.	Oct 2013	B2
8565892	Nayfach-Battilana	Oct 2013	B2
8567612	Kurth et al.	Oct 2013	B2
8568363	Boyden et al.	Oct 2013	B2
8569449	Gorr	Oct 2013	B2
8574660	Weaver et al.	Nov 2013	B2
8585627	Dacey, Jr. et al.	Nov 2013	B2
8591876	Bauman et al.	Nov 2013	B2
8591961	Widgerow	Nov 2013	B2
8592473	Reid	Nov 2013	B2
8603494	Boyden et al.	Dec 2013	B2
8603495	Boyden et al.	Dec 2013	B2
8603496	Boyden et al.	Dec 2013	B2
8604004	Kahne et al.	Dec 2013	B2
8609110	Shanks et al.	Dec 2013	B2
8613937	Boyden et al.	Dec 2013	B2
8617523	Trivedi et al.	Dec 2013	B2
8617542	Madhyastha et al.	Dec 2013	B2
8618149	Melander et al.	Dec 2013	B2
8623340	Kuhn et al.	Jan 2014	B2
8623371	Otto et al.	Jan 2014	B2
8632838	Roth et al.	Jan 2014	B2
8637090	Ohtake et al.	Jan 2014	B2
8641686	Stephan	Feb 2014	B2
8647292	Dacey, Jr. et al.	Feb 2014	B2
8652829	Bellalou et al.	Feb 2014	B2
8653124	Melander et al.	Feb 2014	B2
8658225	Zinreich et al.	Feb 2014	B2
8663616	Butterick et al.	Mar 2014	B2
8680072	Onsoyen et al.	Mar 2014	B2
8680148	Greenberg et al.	Mar 2014	B2
8684732	Jacoby	Apr 2014	B2
8685427	Li et al.	Apr 2014	B2
8685957	Lai et al.	Apr 2014	B1
8691264	Li et al.	Apr 2014	B2
8691288	Myntti	Apr 2014	B2
8697101	Marquais-Bienewald et al.	Apr 2014	B2
8697102	Bukshpan et al.	Apr 2014	B2
8697375	Shirtliff et al.	Apr 2014	B2
8702640	Dacey, Jr. et al.	Apr 2014	B2
8706211	Dacey, Jr. et al.	Apr 2014	B2
8709342	Raad	Apr 2014	B2
8709478	Chang et al.	Apr 2014	B2
8710082	Waters et al.	Apr 2014	B2
8715733	Kadiyala et al.	May 2014	B2
8721583	Boyden et al.	May 2014	B2
8722068	Boyden et al.	May 2014	B2
8725420	Boyden et al.	May 2014	B2
8728467	Olmstead	May 2014	B2
8731840	Boyden et al.	May 2014	B2
8731841	Boyden et al.	May 2014	B2
8731842	Boyden et al.	May 2014	B2
8734718	Dacey, Jr. et al.	May 2014	B2
8741855	Quave et al.	Jun 2014	B2
8748661	Xu et al.	Jun 2014	B2
8753304	Dacey, Jr. et al.	Jun 2014	B2
8753692	Gawande et al.	Jun 2014	B2
8754039	Eckert et al.	Jun 2014	B2
8758781	Ward et al.	Jun 2014	B2
8758824	Lipp et al.	Jun 2014	B2
8762067	Boyden et al.	Jun 2014	B2
8778370	Kramer et al.	Jul 2014	B2
8778387	Tennican et al.	Jul 2014	B2
8778889	Leung	Jul 2014	B2
8779023	Whang et al.	Jul 2014	B2
8784384	Boyden et al.	Jul 2014	B2
8784385	Boyden et al.	Jul 2014	B2
8785399	Giuliani et al.	Jul 2014	B2
8785680	Zhang et al.	Jul 2014	B2
8788211	Boyden et al.	Jul 2014	B2
8788212	Boyden et al.	Jul 2014	B2
8790684	Dave et al.	Jul 2014	B2
8793075	Boyden et al.	Jul 2014	B2
8795727	Gong et al.	Aug 2014	B2
8796252	Rioux et al.	Aug 2014	B2
8798932	Boyden et al.	Aug 2014	B2
8798933	Boyden et al.	Aug 2014	B2
8802059	Fagon et al.	Aug 2014	B2
8802414	Frank et al.	Aug 2014	B2
8808718	Van Der Waal et al.	Aug 2014	B2
8809031	England et al.	Aug 2014	B2
8809314	He et al.	Aug 2014	B1
8821862	Madhyastha et al.	Sep 2014	B2
8821910	Song et al.	Sep 2014	B2
8828910	Aksela et al.	Sep 2014	B2
8829053	Salamone et al.	Sep 2014	B2
8835644	Hoffman et al.	Sep 2014	B2
8840912	Melander et al.	Sep 2014	B2
8846008	Tennican et al.	Sep 2014	B2
8846009	Tennican et al.	Sep 2014	B2
8846605	Ghatnekar	Sep 2014	B2
8849441	Boyden et al.	Sep 2014	B2
8852912	Estell et al.	Oct 2014	B2
8853278	Looper et al.	Oct 2014	B1
8858912	Boyden et al.	Oct 2014	B2
8865909	Srebnik et al.	Oct 2014	B2
8884022	Melander et al.	Nov 2014	B2
8888731	Dacey, Jr. et al.	Nov 2014	B2
8889196	Xu	Nov 2014	B2
8900624	Karandikar et al.	Dec 2014	B2
8906349	Schaeffer-Korbylo et al.	Dec 2014	B2
8906364	Madhyastha	Dec 2014	B2
8906393	Kaplan et al.	Dec 2014	B2
8906898	Hwang et al.	Dec 2014	B1
8906915	De Keersmaecker et al.	Dec 2014	B2
8920826	Bucay-Couto	Dec 2014	B2
8921071	Otto et al.	Dec 2014	B2
8926951	Ratcliff et al.	Jan 2015	B2
8927029	Melander et al.	Jan 2015	B2
8937167	Janetka et al.	Jan 2015	B2
8940911	Luk et al.	Jan 2015	B2
8945142	Schaeffer et al.	Feb 2015	B2
8952192	Sintim et al.	Feb 2015	B2
8956658	Schoenfisch et al.	Feb 2015	B2
8956663	Gordon et al.	Feb 2015	B2
8962029	Schoenfisch et al.	Feb 2015	B2
8962283	Cascao-Pereira et al.	Feb 2015	B2
8968753	Terracciano et al.	Mar 2015	B2
8968765	Chen et al.	Mar 2015	B2
8980299	Dave et al.	Mar 2015	B2
8981139	Schoenfisch et al.	Mar 2015	B2
8992223	Sun et al.	Mar 2015	B2
8992983	Lipp et al.	Mar 2015	B2
8999175	Man et al.	Apr 2015	B2
8999265	Koesdjojo et al.	Apr 2015	B2
9005263	Boyden et al.	Apr 2015	B2
9005643	Melander et al.	Apr 2015	B2
9005680	Fetissova et al.	Apr 2015	B2
9012505	Zhang et al.	Apr 2015	B2
9028878	Baker	May 2015	B2
9029318	Zlotkin et al.	May 2015	B2
9034346	Miller et al.	May 2015	B2
9034612	Lam et al.	May 2015	B2
9034927	Williams et al.	May 2015	B2
9040087	Boyden et al.	May 2015	B2
9044485	Terracciano et al.	Jun 2015	B2
9044531	Dave et al.	Jun 2015	B2
9045550	Zlotkin	Jun 2015	B2
9045712	Dayton et al.	Jun 2015	B2
9050070	Boyden et al.	Jun 2015	B2
9050251	Boyden et al.	Jun 2015	B2
9050317	Boyden et al.	Jun 2015	B2
9056047	Boyden et al.	Jun 2015	B2
9056899	Collins et al.	Jun 2015	B2
9060926	Boyden et al.	Jun 2015	B2
9060931	Boyden et al.	Jun 2015	B2
9060934	Boyden et al.	Jun 2015	B2
9061352	Lipp et al.	Jun 2015	B2
9072688	Boyden et al.	Jul 2015	B2
9072799	Boyden et al.	Jul 2015	B2
9073884	Gerwick et al.	Jul 2015	B2
9078441	Raad	Jul 2015	B2
9084423	Melander et al.	Jul 2015	B2
9084902	Mordas et al.	Jul 2015	B2
9085608	Stensen et al.	Jul 2015	B2
9096703	Li et al.	Aug 2015	B2
9125408	Melander et al.	Sep 2015	B2
9125853	Reynolds	Sep 2015	B2
9131687	Kolter et al.	Sep 2015	B2
9139622	Shanks et al.	Sep 2015	B2
9145395	Melander et al.	Sep 2015	B2
9149648	Dacey, Jr. et al.	Oct 2015	B2
9150453	Li et al.	Oct 2015	B1
9150788	Luk et al.	Oct 2015	B2
9155310	Agrawal et al.	Oct 2015	B2
9156855	Barraud et al.	Oct 2015	B2
9161544	Agrawal et al.	Oct 2015	B2
9161923	Holden	Oct 2015	B2
9161984	Ghatnekar	Oct 2015	B2
9167820	Demuth et al.	Oct 2015	B2
9169319	Alarcon et al.	Oct 2015	B2
9180157	Widgerow	Nov 2015	B2
9180158	Widgerow	Nov 2015	B2
9181290	Liu et al.	Nov 2015	B2
9187501	Schoenfisch et al.	Nov 2015	B2
9193767	Sello	Nov 2015	B2
9193962	Bornscheuer et al.	Nov 2015	B2
9198957	Ratner et al.	Dec 2015	B2
9212286	Whiteford et al.	Dec 2015	B2
9220267	Williams et al.	Dec 2015	B2
9221213	Dou et al.	Dec 2015	B2
9221765	Melander et al.	Dec 2015	B2
9221875	Yang et al.	Dec 2015	B2
9227980	Scherman et al.	Jan 2016	B2
9233158	Lipp et al.	Jan 2016	B2
9242951	Meijler et al.	Jan 2016	B2
9243036	Atreya et al.	Jan 2016	B2
9243267	Lam et al.	Jan 2016	B2
9247734	Sabin	Feb 2016	B2
9253987	Tennican et al.	Feb 2016	B2
9265820	Shirtliff et al.	Feb 2016	B2
9271493	Cegelski et al.	Mar 2016	B2
9271502	Sabin	Mar 2016	B2
9273084	Kahne et al.	Mar 2016	B2
9273096	Yang et al.	Mar 2016	B2
9283280	Maggio	Mar 2016	B2
9283283	Giammona et al.	Mar 2016	B2
9284351	Zlotkin	Mar 2016	B2
9289442	Doxey et al.	Mar 2016	B2
9289449	Sershen et al.	Mar 2016	B2
9295257	Melander et al.	Mar 2016	B2
9308298	Zhang	Apr 2016	B2
9320740	Terracciano et al.	Apr 2016	B2
9321030	Sukhishvili et al.	Apr 2016	B2
9326511	Love et al.	May 2016	B2
9326924	Fourre et al.	May 2016	B1
9326925	Fourre et al.	May 2016	B1
9334466	Aehle et al.	May 2016	B2
9339525	O'Neil et al.	May 2016	B2
9340802	Trevethick	May 2016	B2
9351491	Melander et al.	May 2016	B2
9351492	Quave et al.	May 2016	B2
9358274	Olmstead	Jun 2016	B2
9359275	Watnick et al.	Jun 2016	B2
9364491	O'Neil et al.	Jun 2016	B2
9370187	Reid et al.	Jun 2016	B2
9376430	Hoffman et al.	Jun 2016	B2
9387189	Glasnapp	Jul 2016	B2
9393261	Sternoff et al.	Jul 2016	B2
9394529	Barton et al.	Jul 2016	B2
9402394	Tang et al.	Aug 2016	B2
9403851	Schoenfisch et al.	Aug 2016	B2
9403852	Schoenfisch et al.	Aug 2016	B2
9408393	Baker	Aug 2016	B2
9415144	Anzai et al.	Aug 2016	B2
9423532	Jewhurst et al.	Aug 2016	B2
9427605	Peters	Aug 2016	B2
9433527	Varga et al.	Sep 2016	B2
9433576	Lipp et al.	Sep 2016	B2
9439433	Looper et al.	Sep 2016	B2
9439436	Melander et al.	Sep 2016	B2
9439803	Varga et al.	Sep 2016	B2
9446090	Bevilacqua et al.	Sep 2016	B2
9452107	Bilgili et al.	Sep 2016	B2
9469616	Li et al.	Oct 2016	B2
9469861	Blake et al.	Oct 2016	B2
9474831	Boyden et al.	Oct 2016	B2
9480260	Whang et al.	Nov 2016	B2
9480541	Falcone et al.	Nov 2016	B2
9487453	Sabin	Nov 2016	B2
9492596	Herweck et al.	Nov 2016	B2
9499419	de Rijk	Nov 2016	B2
9499594	Schuch et al.	Nov 2016	B2
9499844	Lam et al.	Nov 2016	B2
9504688	Ginsburg et al.	Nov 2016	B2
9504739	Berkes et al.	Nov 2016	B2
9512382	Dayton et al.	Dec 2016	B2
9518013	Li et al.	Dec 2016	B2
9526738	Stasko et al.	Dec 2016	B2
9526766	Hakansson et al.	Dec 2016	B2
9539233	Ohtake et al.	Jan 2017	B2
9539367	Britigan et al.	Jan 2017	B2
9539373	Jones et al.	Jan 2017	B2
9540389	Opperman et al.	Jan 2017	B2
9540471	Hrabie et al.	Jan 2017	B2
9550005	Lin et al.	Jan 2017	B2
9554971	Xu et al.	Jan 2017	B2
9555116	Folan	Jan 2017	B2
9556109	Caran et al.	Jan 2017	B1
9556223	Stensen et al.	Jan 2017	B2
9561168	Schaeffer-Korbylo et al.	Feb 2017	B2
9562085	Nibbering et al.	Feb 2017	B2
9562254	Potnis et al.	Feb 2017	B2
9565857	Raad et al.	Feb 2017	B2
9566247	Koo et al.	Feb 2017	B2
9566341	Stinchcomb et al.	Feb 2017	B1
9566372	Handa et al.	Feb 2017	B2
9567362	Janetka et al.	Feb 2017	B2
9574185	Yim et al.	Feb 2017	B2
9574189	Franch et al.	Feb 2017	B2
9585922	Lang et al.	Mar 2017	B2
9586871	Sabin	Mar 2017	B2
9591852	Mordas et al.	Mar 2017	B2
9592299	Sershen et al.	Mar 2017	B2
9592324	Herweck et al.	Mar 2017	B2
9597407	Eckert et al.	Mar 2017	B2
9603859	Genberg et al.	Mar 2017	B2
9603877	Chang et al.	Mar 2017	B2
9603977	Ghigo et al.	Mar 2017	B2
9603979	Ghigo et al.	Mar 2017	B2
9612246	Bruce et al.	Apr 2017	B2
9617176	Cuero Rengifo et al.	Apr 2017	B2
9622481	Gawande et al.	Apr 2017	B2
9631100	Reches	Apr 2017	B2
9642798	Lipp et al.	May 2017	B2
9642829	Seneviratne et al.	May 2017	B2
9644194	Yim et al.	May 2017	B2
9648876	Jackson et al.	May 2017	B2
9648880	Kaufman et al.	May 2017	B2
9657132	Hanson et al.	May 2017	B2
9669001	Bowler et al.	Jun 2017	B2
9669041	Stasko et al.	Jun 2017	B2
9675077	Parsons	Jun 2017	B2
9675736	Burgess et al.	Jun 2017	B2
9682023	Ratcliff et al.	Jun 2017	B2
9683197	Aizenberg et al.	Jun 2017	B2
9687001	Vujanovic et al.	Jun 2017	B2
9687670	Dacey, Jr. et al.	Jun 2017	B2
9694114	Lucchino et al.	Jul 2017	B2
9700058	Zlotkin	Jul 2017	B2
9700650	Gong et al.	Jul 2017	B2
9706778	Berkes et al.	Jul 2017	B2
9713631	Berkes et al.	Jul 2017	B2
9713652	Schoenfisch et al.	Jul 2017	B2
9717251	Sabin	Aug 2017	B2
9717765	Berkes et al.	Aug 2017	B2
9718739	Sabin	Aug 2017	B2
9723833	Kolari et al.	Aug 2017	B2
9723837	Melander et al.	Aug 2017	B2
9723843	Olson et al.	Aug 2017	B2
9724353	Chandorkar et al.	Aug 2017	B2
9732124	Zlotkin	Aug 2017	B2
9737561	Stasko et al.	Aug 2017	B2
9737571	Zlotkin et al.	Aug 2017	B2
9737591	Olmstead	Aug 2017	B2
9744130	Lipp et al.	Aug 2017	B2
9744270	Boluk et al.	Aug 2017	B2
9746407	Bernardi et al.	Aug 2017	B2
9757397	Kougoulos et al.	Sep 2017	B2
9764069	Roth et al.	Sep 2017	B2
9770418	Rahimipour et al.	Sep 2017	B2
9775853	Troxel et al.	Oct 2017	B2
9777050	Zlotkin et al.	Oct 2017	B2
9782388	Shaw et al.	Oct 2017	B2
9782423	O'Neil et al.	Oct 2017	B2
9789005	Tennican et al.	Oct 2017	B2
9789057	Riley et al.	Oct 2017	B2
9795762	Bouchard et al.	Oct 2017	B2
9801982	Herweck et al.	Oct 2017	B2
9808496	Luc et al.	Nov 2017	B2
9814719	Sun et al.	Nov 2017	B2
9815794	Melander et al.	Nov 2017	B2
9833528	Alarcon et al.	Dec 2017	B2
9834744	Ludwig et al.	Dec 2017	B2
9839219	Looper et al.	Dec 2017	B2
9844679	Nayfach-Battilana	Dec 2017	B2
9849182	McInroy et al.	Dec 2017	B2
9850322	Schoenfisch et al.	Dec 2017	B2
9854807	Sabin	Jan 2018	B2
9855211	Doxey et al.	Jan 2018	B2
9856225	Huigens, III et al.	Jan 2018	B2
9856283	Oscarson et al.	Jan 2018	B2
9861701	Sershen et al.	Jan 2018	B2
9861723	Hanson et al.	Jan 2018	B2
9862837	Reches	Jan 2018	B2
9867906	Matheny	Jan 2018	B2
9872491	Gambogi et al.	Jan 2018	B2
9872893	Nelson	Jan 2018	B2
9872906	Terracciano et al.	Jan 2018	B2
9872917	Tang et al.	Jan 2018	B2
9877983	Onsoyen et al.	Jan 2018	B2
9888691	Karandikar et al.	Feb 2018	B2
9889077	Schaeffer-Korbylo et al.	Feb 2018	B2
9895469	Schultz et al.	Feb 2018	B2
9907584	Mangiardi	Mar 2018	B2
9913476	Agrawal et al.	Mar 2018	B2
9914750	Gorr	Mar 2018	B2
9918473	Melander et al.	Mar 2018	B2
9919012	Berkes et al.	Mar 2018	B2
9919072	Stasko et al.	Mar 2018	B2
9919079	Matheny	Mar 2018	B2
9925205	Malinin	Mar 2018	B2
9926526	Newman et al.	Mar 2018	B2
9931300	Bilgili et al.	Apr 2018	B2
9931381	Olmstead	Apr 2018	B2
9932484	Aizenberg et al.	Apr 2018	B2
9937104	Xu et al.	Apr 2018	B2
9956319	Mansouri et al.	May 2018	B2
9956322	Pichler-Wilhelm et al.	May 2018	B2
9957289	Janetka et al.	May 2018	B2
9957395	Whiteford et al.	May 2018	B2
9975857	Melander et al.	May 2018	B2
9993533	Pellico	Jun 2018	B2
10004771	Berkes et al.	Jun 2018	B2
10016525	Adams et al.	Jul 2018	B2
10034478	Krasnow et al.	Jul 2018	B2
10071103	Sengupta et al.	Sep 2018	B2
10072161	Margel et al.	Sep 2018	B2
10086025	Berkes et al.	Oct 2018	B2
10104862	Vujanovic et al.	Oct 2018	B2
10106580	Sello	Oct 2018	B2
10172362	Wood et al.	Jan 2019	B2
10208241	Agrawal et al.	Feb 2019	B2
10221398	Cady et al.	Mar 2019	B2
10266793	Labib et al.	Apr 2019	B2
10273260	Janetka et al.	Apr 2019	B2
10287576	Franch et al.	May 2019	B2
10301254	Wuest et al.	May 2019	B2
10308920	Bornscheuer et al.	Jun 2019	B2
10329549	Steer et al.	Jun 2019	B2
10342849	Glasnapp	Jul 2019	B2
10350217	Kaufman et al.	Jul 2019	B2
10376465	Lipp et al.	Aug 2019	B2
10376538	Stasko et al.	Aug 2019	B2
10440955	Looper et al.	Oct 2019	B2
10487316	Barton et al.	Nov 2019	B2
10500140	Wellings	Dec 2019	B2
10508136	Zlotkin	Dec 2019	B2
10513671	Lant et al.	Dec 2019	B2
10526359	Oscarson et al.	Jan 2020	B2
10538730	Nguyen et al.	Jan 2020	B2
10570364	Nguyen et al.	Feb 2020	B2
10570401	Rickard et al.	Feb 2020	B2
10577743	van Buskirk	Mar 2020	B2
10589039	DeHaan et al.	Mar 2020	B2
10597314	Frail et al.	Mar 2020	B2
10611656	Buschmann	Apr 2020	B2
10653140	Davies	May 2020	B2
10681914	Dale et al.	Jun 2020	B2
10687535	Wingfield	Jun 2020	B2
10689610	Nguyen et al.	Jun 2020	B2
10711253	Cady et al.	Jul 2020	B2
10723976	Lant et al.	Jul 2020	B2
10738200	Margel et al.	Aug 2020	B2
10806871	DeHaan et al.	Oct 2020	B2
10835510	Baker et al.	Nov 2020	B2
10835556	Pesavento	Nov 2020	B2
10837004	Cady et al.	Nov 2020	B2
10849324	Sawyer et al.	Dec 2020	B2
10849729	Sagel et al.	Dec 2020	B2
20020066702	Liu	Jun 2002	A1
20020123077	O'Toole et al.	Sep 2002	A1
20030035779	Brown et al.	Feb 2003	A1
20030065292	Darouiche et al.	Apr 2003	A1
20030079758	Siegel et al.	May 2003	A1
20030091641	Tiller et al.	May 2003	A1
20030099602	Levin et al.	May 2003	A1
20030103912	Levin et al.	Jun 2003	A1
20030111420	Dresty, Jr. et al.	Jun 2003	A1
20030121868	Barak	Jul 2003	A1
20030129144	Scott et al.	Jul 2003	A1
20030134783	Harshey et al.	Jul 2003	A1
20030153059	Pilkington et al.	Aug 2003	A1
20030178044	Brown et al.	Sep 2003	A1
20040083556	Kurauchi	May 2004	A1
20040097402	Bassler et al.	May 2004	A1
20040110738	Gillis et al.	Jun 2004	A1
20040116371	Romeo et al.	Jun 2004	A1
20040116845	Darouiche et al.	Jun 2004	A1
20040129112	Gillis et al.	Jul 2004	A1
20040131698	Gillis et al.	Jul 2004	A1
20040156883	Brown et al.	Aug 2004	A1
20040156884	Brown et al.	Aug 2004	A1
20040176312	Gillis	Sep 2004	A1
20040191329	Burrell et al.	Sep 2004	A1
20040235914	Ammendola et al.	Nov 2004	A1
20040241107	Burzynski et al.	Dec 2004	A1
20040254545	Rider et al.	Dec 2004	A1
20050003725	Hill et al.	Jan 2005	A1
20050008671	Van Antwerp	Jan 2005	A1
20050013836	Raad	Jan 2005	A1
20050032093	Romeo et al.	Feb 2005	A1
20050049181	Madhyastha	Mar 2005	A1
20050064019	Hill et al.	Mar 2005	A1
20050084545	Pipko et al.	Apr 2005	A1
20050095245	Riley et al.	May 2005	A1
20050143286	Singh et al.	Jun 2005	A1
20050147719	Hill et al.	Jul 2005	A1
20050151117	Man et al.	Jul 2005	A1
20050158263	Rioux et al.	Jul 2005	A1
20050159324	Man et al.	Jul 2005	A1
20050161636	Man et al.	Jul 2005	A1
20050163896	Man et al.	Jul 2005	A1
20050202424	Ausubel et al.	Sep 2005	A1
20050233950	Madhyastha	Oct 2005	A1
20050249695	Tiller et al.	Nov 2005	A1
20050260181	Girsh	Nov 2005	A1
20060001865	Bellalou et al.	Jan 2006	A1
20060018945	Britigan et al.	Jan 2006	A1
20060034782	Brown et al.	Feb 2006	A1
20060067951	Cvitkovitch et al.	Mar 2006	A1
20060099579	Hillman	May 2006	A1
20060110456	Teo et al.	May 2006	A1
20060113506	Man et al.	Jun 2006	A1
20060120916	Kolari et al.	Jun 2006	A1
20060138058	Barak	Jun 2006	A1
20060162014	Jaffe	Jul 2006	A1
20060165648	Degenhardt et al.	Jul 2006	A1
20060177384	Brown	Aug 2006	A1
20060177490	Massouda	Aug 2006	A1
20060180552	Downs	Aug 2006	A1
20060197058	Martin	Sep 2006	A1
20060224103	Rontal	Oct 2006	A1
20060243297	Brown	Nov 2006	A1
20060264497	Zeligs	Nov 2006	A1
20060276483	Surber et al.	Dec 2006	A1
20070003603	Karandikar et al.	Jan 2007	A1
20070009566	Balaban	Jan 2007	A1
20070010856	Cohen	Jan 2007	A1
20070014739	Eldridge et al.	Jan 2007	A1
20070020309	Alberte et al.	Jan 2007	A1
20070049641	Tirouvanziam et al.	Mar 2007	A1
20070053849	Doyle et al.	Mar 2007	A1
20070062884	Sun et al.	Mar 2007	A1
20070083156	Muto et al.	Apr 2007	A1
20070083677	Cecka et al.	Apr 2007	A1
20070098651	Leung	May 2007	A1
20070098674	Bukshpan et al.	May 2007	A1
20070098745	Bruno	May 2007	A1
20070106232	Rider II et al.	May 2007	A1
20070109535	Maier et al.	May 2007	A1
20070116750	Wolcott	May 2007	A1
20070116798	Brown et al.	May 2007	A1
20070134171	Dodds et al.	Jun 2007	A1
20070134649	Kolari et al.	Jun 2007	A1
20070140990	Fetissova et al.	Jun 2007	A1
20070190090	Brown	Aug 2007	A1
20070202342	Whiteford et al.	Aug 2007	A1
20070202566	Bornscheuer et al.	Aug 2007	A1
20070202770	Penalva	Aug 2007	A1
20070207095	Davies	Sep 2007	A1
20070224161	Sun et al.	Sep 2007	A1
20070231406	Bucalo et al.	Oct 2007	A1
20070232167	Hill et al.	Oct 2007	A1
20070244059	Karaolis	Oct 2007	A1
20070253919	Boyd	Nov 2007	A1
20070258913	Rossel	Nov 2007	A1
20070264310	Hissong et al.	Nov 2007	A1
20070264342	Oliver et al.	Nov 2007	A1
20070264353	Myntti et al.	Nov 2007	A1
20080014247	Lu et al.	Jan 2008	A1
20080014278	Lu et al.	Jan 2008	A1
20080014286	Gillis et al.	Jan 2008	A1
20080020127	Whiteford et al.	Jan 2008	A1
20080021212	Whiteford et al.	Jan 2008	A1
20080044491	Lyczak et al.	Feb 2008	A1
20080045439	Held	Feb 2008	A1
20080050452	Chen et al.	Feb 2008	A1
20080075730	Storey et al.	Mar 2008	A1
20080085282	Yu et al.	Apr 2008	A1
20080085866	Greenberg et al.	Apr 2008	A1
20080095812	Code	Apr 2008	A1
20080107707	Lawson et al.	May 2008	A1
20080109017	Herweck et al.	May 2008	A1
20080113001	Herweck et al.	May 2008	A1
20080138634	Morris et al.	Jun 2008	A1
20080181923	Melander et al.	Jul 2008	A1
20080193562	Code	Aug 2008	A1
20080206183	Commeyras et al.	Aug 2008	A1
20080206276	Otto et al.	Aug 2008	A1
20080206305	Herweck et al.	Aug 2008	A1
20080207581	Whiteford et al.	Aug 2008	A1
20080237028	Kislev	Oct 2008	A1
20080248087	Hill et al.	Oct 2008	A1
20080253976	Scott et al.	Oct 2008	A1
20080268189	Sun et al.	Oct 2008	A1
20080286847	Jaffe	Nov 2008	A1
20080293607	Jones et al.	Nov 2008	A1
20080305531	Lam et al.	Dec 2008	A1
20080317815	Davies	Dec 2008	A1
20080318268	Olson et al.	Dec 2008	A1
20080318269	Olson et al.	Dec 2008	A1
20090005339	Scholz et al.	Jan 2009	A1
20090033930	Maier et al.	Feb 2009	A1
20090048324	Jaffe	Feb 2009	A1
20090050575	Barak	Feb 2009	A1
20090069406	Lee et al.	Mar 2009	A1
20090074825	Sun et al.	Mar 2009	A1
20090099533	Montelaro et al.	Apr 2009	A1
20090112186	Adams	Apr 2009	A1
20090133810	Penalva	May 2009	A1
20090143230	Melander et al.	Jun 2009	A1
20090145859	Man et al.	Jun 2009	A1
20090148342	Bromberg et al.	Jun 2009	A1
20090148492	Dave et al.	Jun 2009	A1
20090155215	Collins et al.	Jun 2009	A1
20090163964	Boyden et al.	Jun 2009	A1
20090163965	Boyden et al.	Jun 2009	A1
20090163977	Boyden et al.	Jun 2009	A1
20090171263	Boyden et al.	Jul 2009	A1
20090171388	Dave et al.	Jul 2009	A1
20090177139	Boyden et al.	Jul 2009	A1
20090177254	Boyden et al.	Jul 2009	A1
20090181106	Gordon et al.	Jul 2009	A1
20090192227	Tirouvanziam et al.	Jul 2009	A1
20090202454	Prencipe et al.	Aug 2009	A1
20090202516	Olmstead	Aug 2009	A1
20090214603	Demuth et al.	Aug 2009	A1
20090214628	de Rijk	Aug 2009	A1
20090221704	Aksela et al.	Sep 2009	A1
20090226541	Scholz et al.	Sep 2009	A1
20090238811	McDaniel et al.	Sep 2009	A1
20090238923	Shaw et al.	Sep 2009	A1
20090247422	Hillman	Oct 2009	A1
20090253613	Gabbai	Oct 2009	A1
20090260632	Abnousi et al.	Oct 2009	A1
20090263438	Melander et al.	Oct 2009	A1
20090264300	Franch et al.	Oct 2009	A1
20090269323	Luk et al.	Oct 2009	A1
20090270475	Melander et al.	Oct 2009	A1
20090297495	Kerovuo et al.	Dec 2009	A1
20090318382	Ghigo et al.	Dec 2009	A1
20090324574	Mathur et al.	Dec 2009	A1
20090324820	Chartier	Dec 2009	A1
20100015245	Harrison et al.	Jan 2010	A1
20100016767	Jones et al.	Jan 2010	A1
20100021587	Chang et al.	Jan 2010	A1
20100028396	Ward et al.	Feb 2010	A1
20100037890	Surber et al.	Feb 2010	A1
20100040560	Surber et al.	Feb 2010	A1
20100048446	Cascao-Pereira et al.	Feb 2010	A1
20100055086	Raad	Mar 2010	A1
20100056415	Rong et al.	Mar 2010	A1
20100059433	Freeman et al.	Mar 2010	A1
20100087530	Man et al.	Apr 2010	A1
20100096340	Barak	Apr 2010	A1
20100099599	Michalow et al.	Apr 2010	A1
20100111830	Boyden et al.	May 2010	A1
20100111831	Boyden et al.	May 2010	A1
20100111832	Boyden et al.	May 2010	A1
20100111833	Boyden et al.	May 2010	A1
20100111834	Boyden et al.	May 2010	A1
20100111835	Boyden et al.	May 2010	A1
20100111836	Boyden et al.	May 2010	A1
20100111837	Boyden et al.	May 2010	A1
20100111841	Boyden et al.	May 2010	A1
20100111842	Boyden et al.	May 2010	A1
20100111843	Boyden et al.	May 2010	A1
20100111844	Boyden et al.	May 2010	A1
20100111845	Boyden et al.	May 2010	A1
20100111846	Boyden et al.	May 2010	A1
20100111847	Boyden et al.	May 2010	A1
20100111848	Boyden et al.	May 2010	A1
20100111849	Boyden et al.	May 2010	A1
20100111850	Boyden et al.	May 2010	A1
20100111854	Boyden et al.	May 2010	A1
20100111855	Boyden et al.	May 2010	A1
20100111857	Boyden et al.	May 2010	A1
20100111938	Boyden et al.	May 2010	A1
20100112067	Boyden et al.	May 2010	A1
20100112068	Boyden et al.	May 2010	A1
20100112093	Boyden et al.	May 2010	A1
20100113614	Boyden et al.	May 2010	A1
20100113615	Boyden et al.	May 2010	A1
20100114013	Boyden et al.	May 2010	A1
20100114267	Boyden et al.	May 2010	A1
20100114268	Boyden et al.	May 2010	A1
20100114348	Boyden et al.	May 2010	A1
20100114496	Boyden et al.	May 2010	A1
20100114497	Boyden et al.	May 2010	A1
20100114545	Boyden et al.	May 2010	A1
20100114546	Boyden et al.	May 2010	A1
20100114547	Boyden et al.	May 2010	A1
20100114592	Boyden et al.	May 2010	A1
20100119557	Boyden et al.	May 2010	A1
20100121466	Boyden et al.	May 2010	A1
20100129297	Vezin	May 2010	A1
20100129466	Marques et al.	May 2010	A1
20100130450	Lewis et al.	May 2010	A1
20100133114	Bukshpan et al.	Jun 2010	A1
20100136072	Haidar et al.	Jun 2010	A1
20100136112	Martin	Jun 2010	A1
20100136143	Bukshpan	Jun 2010	A1
20100143243	Boyden et al.	Jun 2010	A1
20100145412	Boyden et al.	Jun 2010	A1
20100152101	Reid	Jun 2010	A1
20100152651	Boyden et al.	Jun 2010	A1
20100152880	Boyden et al.	Jun 2010	A1
20100158957	Surber et al.	Jun 2010	A1
20100158966	Reid et al.	Jun 2010	A1
20100158967	Reid et al.	Jun 2010	A1
20100163576	Boyden et al.	Jul 2010	A1
20100166673	Surber et al.	Jul 2010	A1
20100168900	Boyden et al.	Jul 2010	A1
20100173366	Rhimi et al.	Jul 2010	A1
20100174346	Boyden et al.	Jul 2010	A1
20100178268	Bukshpan et al.	Jul 2010	A1
20100183693	Martin	Jul 2010	A1
20100183738	Kramer et al.	Jul 2010	A1
20100185174	Boyden et al.	Jul 2010	A1
20100187728	Boyden et al.	Jul 2010	A1
20100189706	Chang et al.	Jul 2010	A1
20100210745	McDaniel et al.	Aug 2010	A1
20100221198	Ratcliff et al.	Sep 2010	A1
20100233146	McDaniel	Sep 2010	A1
20100234792	Dacey, Jr. et al.	Sep 2010	A1
20100234793	Dacey, Jr. et al.	Sep 2010	A1
20100240017	Dacey, Jr. et al.	Sep 2010	A1
20100241048	Dacey, Jr. et al.	Sep 2010	A1
20100241049	Dacey, Jr. et al.	Sep 2010	A1
20100241050	Dacey, Jr. et al.	Sep 2010	A1
20100241051	Dacey, Jr. et al.	Sep 2010	A1
20100241052	Dacey, Jr. et al.	Sep 2010	A1
20100241053	Dacey, Jr. et al.	Sep 2010	A1
20100241054	Dacey, Jr. et al.	Sep 2010	A1
20100241055	Dacey, Jr. et al.	Sep 2010	A1
20100247374	Pellet	Sep 2010	A1
20100249692	Dacey, Jr. et al.	Sep 2010	A1
20100254967	Frank et al.	Oct 2010	A1
20100255178	Leander et al.	Oct 2010	A1
20100266716	Olson et al.	Oct 2010	A1
20100269731	Tofte Jespersen et al.	Oct 2010	A1
20100272768	Bukshpan et al.	Oct 2010	A1
20100286198	Bringmann et al.	Nov 2010	A1
20100292629	Dacey, Jr. et al.	Nov 2010	A1
20100298208	Cohen et al.	Nov 2010	A1
20100305062	Onsoyen et al.	Dec 2010	A1
20100316643	Eckert et al.	Dec 2010	A1
20100322903	Collins et al.	Dec 2010	A1
20110003001	Baker	Jan 2011	A1
20110005997	Kurth et al.	Jan 2011	A1
20110008402	Madhyastha et al.	Jan 2011	A1
20110008786	Yu et al.	Jan 2011	A1
20110015300	Whiteford et al.	Jan 2011	A1
20110027252	Aehle et al.	Feb 2011	A1
20110027384	Kishen et al.	Feb 2011	A1
20110029076	Paletta et al.	Feb 2011	A1
20110033520	Mather et al.	Feb 2011	A1
20110033882	Aehle et al.	Feb 2011	A1
20110039761	Eckert et al.	Feb 2011	A1
20110039762	Eckert et al.	Feb 2011	A1
20110039763	Eckert et al.	Feb 2011	A1
20110046041	Neesham-Grenon et al.	Feb 2011	A1
20110052664	Tennican et al.	Mar 2011	A1
20110059062	Pellico	Mar 2011	A1
20110070376	Wales et al.	Mar 2011	A1
20110077192	Giuliani et al.	Mar 2011	A1
20110086101	Madhyastha et al.	Apr 2011	A1
20110098323	Opperman et al.	Apr 2011	A1
20110104179	Reynolds et al.	May 2011	A1
20110105376	England et al.	May 2011	A1
20110105825	Nayfach-Battilana	May 2011	A1
20110110998	Marquais-Bienewald et al.	May 2011	A1
20110117067	Esteghlalian et al.	May 2011	A1
20110117158	Melander et al.	May 2011	A1
20110117160	Bruno	May 2011	A1
20110119774	Zlotkin et al.	May 2011	A1
20110124716	Passineau	May 2011	A1
20110129454	Olmstead	Jun 2011	A1
20110135621	Miller et al.	Jun 2011	A1
20110144566	Dacey, Jr. et al.	Jun 2011	A1
20110150765	Boyden et al.	Jun 2011	A1
20110150819	Melander et al.	Jun 2011	A1
20110152176	Horswill	Jun 2011	A1
20110152750	Dacey, Jr. et al.	Jun 2011	A1
20110152751	Dacey, Jr. et al.	Jun 2011	A1
20110152752	Dacey, Jr. et al.	Jun 2011	A1
20110152789	Dacey, Jr. et al.	Jun 2011	A1
20110152790	Dacey, Jr. et al.	Jun 2011	A1
20110152978	Dacey, Jr. et al.	Jun 2011	A1
20110160643	Dacey, Jr. et al.	Jun 2011	A1
20110160644	Dacey, Jr. et al.	Jun 2011	A1
20110160681	Dacey, Jr. et al.	Jun 2011	A1
20110171123	Shirtliff et al.	Jul 2011	A1
20110171189	Olmstead	Jul 2011	A1
20110171489	Dou et al.	Jul 2011	A1
20110172704	Bleier et al.	Jul 2011	A1
20110177048	Olmstead	Jul 2011	A1
20110177049	Olmstead	Jul 2011	A1
20110177050	Olmstead	Jul 2011	A1
20110177111	Shirtliff et al.	Jul 2011	A1
20110177148	Dicosimo et al.	Jul 2011	A1
20110178182	Gabbai	Jul 2011	A1
20110182873	Olmstead	Jul 2011	A1
20110182874	Olmstead	Jul 2011	A1
20110182959	Cahill et al.	Jul 2011	A1
20110201692	Raad	Aug 2011	A1
20110207816	Jaffe	Aug 2011	A1
20110208021	Goodall et al.	Aug 2011	A1
20110208023	Goodall et al.	Aug 2011	A1
20110208026	Goodall et al.	Aug 2011	A1
20110217312	Otto et al.	Sep 2011	A1
20110217544	Young et al.	Sep 2011	A1
20110220155	Man et al.	Sep 2011	A1
20110229586	Barak	Sep 2011	A1
20110236453	Stensen et al.	Sep 2011	A1
20110236769	Xie et al.	Sep 2011	A1
20110250290	Marques et al.	Oct 2011	A1
20110256187	Hortelano et al.	Oct 2011	A1
20110262511	Love et al.	Oct 2011	A1
20110266724	Hulseman et al.	Nov 2011	A1
20110274730	Ceri et al.	Nov 2011	A1
20110275518	Marques et al.	Nov 2011	A1
20110275912	Boyden et al.	Nov 2011	A1
20110280920	Zlotkin et al.	Nov 2011	A1
20110281921	Srebnik et al.	Nov 2011	A1
20110294668	Melander et al.	Dec 2011	A1
20110295088	Boyden et al.	Dec 2011	A1
20110295089	Boyden et al.	Dec 2011	A1
20110295090	Boyden et al.	Dec 2011	A1
20110300235	Myntti	Dec 2011	A1
20110301076	Stensen et al.	Dec 2011	A1
20110305872	Li et al.	Dec 2011	A1
20110305881	Schultz et al.	Dec 2011	A1
20110305895	Roth et al.	Dec 2011	A1
20110305898	Zhang et al.	Dec 2011	A1
20110305909	Weaver et al.	Dec 2011	A1
20110306699	Whang et al.	Dec 2011	A1
20110311647	Gawande et al.	Dec 2011	A1
20110319808	Bowler et al.	Dec 2011	A1
20120003163	Mordas et al.	Jan 2012	A1
20120010187	Hoffman et al.	Jan 2012	A1
20120010481	Goodall et al.	Jan 2012	A1
20120015870	Zlotkin	Jan 2012	A1
20120020896	Trivedi et al.	Jan 2012	A1
20120036767	Larach	Feb 2012	A1
20120039945	Scott et al.	Feb 2012	A1
20120040030	Zinreich et al.	Feb 2012	A1
20120041285	Goodall et al.	Feb 2012	A1
20120041286	Goodall et al.	Feb 2012	A1
20120041287	Goodall et al.	Feb 2012	A1
20120045817	Estell et al.	Feb 2012	A1
20120052052	Xi et al.	Mar 2012	A1
20120058076	Widgerow	Mar 2012	A1
20120058167	Widgerow	Mar 2012	A1
20120058169	Olson et al.	Mar 2012	A1
20120058933	Gorr	Mar 2012	A1
20120077736	Oh et al.	Mar 2012	A1
20120087887	Hen et al.	Apr 2012	A1
20120088671	Quave et al.	Apr 2012	A1
20120094007	Fehr et al.	Apr 2012	A1
20120101738	Boyden et al.	Apr 2012	A1
20120107258	Kuhn et al.	May 2012	A1
20120109613	Boyden et al.	May 2012	A1
20120122729	Musken et al.	May 2012	A1
20120128599	Schaeffer-Korbylo et al.	May 2012	A1
20120128783	Boyden et al.	May 2012	A1
20120129794	Dowd et al.	May 2012	A1
20120134951	Stasko et al.	May 2012	A1
20120135925	Meijler et al.	May 2012	A1
20120136323	Stasko et al.	May 2012	A1
20120142583	Singh et al.	Jun 2012	A1
20120149631	Delatour et al.	Jun 2012	A1
20120150119	Schaeffer et al.	Jun 2012	A1
20120152149	Mijolovic et al.	Jun 2012	A1
20120156645	Jacoby	Jun 2012	A1
20120157548	Mijolovic et al.	Jun 2012	A1
20120160779	Barak	Jun 2012	A1
20120164069	Boyden et al.	Jun 2012	A1
20120171129	Melander et al.	Jul 2012	A1
20120178971	Khan et al.	Jul 2012	A1
20120189682	O'Neil et al.	Jul 2012	A1
20120201869	Burzell	Aug 2012	A1
20120209090	Goodall et al.	Aug 2012	A1
20120210467	Barton et al.	Aug 2012	A1
20120213697	Friedman et al.	Aug 2012	A1
20120219638	Olson et al.	Aug 2012	A1
20120225098	Kaplan et al.	Sep 2012	A1
20120238644	Gong et al.	Sep 2012	A1
20120244126	Collins et al.	Sep 2012	A1
20120252101	Chang et al.	Oct 2012	A1
20120258089	Madhyastha et al.	Oct 2012	A1
20120258141	Scott et al.	Oct 2012	A9
20120263793	Vitaliano	Oct 2012	A1
20120283165	Man et al.	Nov 2012	A1
20120283174	Reynolds et al.	Nov 2012	A1
20120288566	Friedman et al.	Nov 2012	A1
20120288571	Tennican et al.	Nov 2012	A1
20120289591	Folan	Nov 2012	A1
20120294900	Sintim et al.	Nov 2012	A1
20120301433	Lu et al.	Nov 2012	A1
20120301481	Otto et al.	Nov 2012	A1
20120308632	Ghigo et al.	Dec 2012	A1
20120309701	Janetka et al.	Dec 2012	A1
20120315260	Ivanova et al.	Dec 2012	A1
20120321566	Liu et al.	Dec 2012	A1
20120328534	Butterick et al.	Dec 2012	A1
20120328577	Melander et al.	Dec 2012	A1
20120328671	O'Neil et al.	Dec 2012	A1
20120328683	Song et al.	Dec 2012	A1
20120328684	Shanks et al.	Dec 2012	A1
20120328708	Van Der Waal et al.	Dec 2012	A1
20120328713	Olson et al.	Dec 2012	A1
20120329675	Olson et al.	Dec 2012	A1
20120329746	Reid	Dec 2012	A1
20130005029	Cascao-Pereira et al.	Jan 2013	A1
20130011332	Boyden et al.	Jan 2013	A1
20130011887	Dayton et al.	Jan 2013	A1
20130022553	Xu et al.	Jan 2013	A1
20130022578	Newman et al.	Jan 2013	A1
20130022643	Sternoff et al.	Jan 2013	A1
20130029981	De Keersmaecker et al.	Jan 2013	A1
20130039978	Schwarz et al.	Feb 2013	A1
20130045182	Gong et al.	Feb 2013	A1
20130052250	Burgess et al.	Feb 2013	A1
20130058983	Baker	Mar 2013	A1
20130059096	Losick et al.	Mar 2013	A1
20130059113	Hatton et al.	Mar 2013	A1
20130059929	Koehler et al.	Mar 2013	A1
20130071319	Boyden et al.	Mar 2013	A1
20130071439	Losick et al.	Mar 2013	A1
20130095184	Lyczak et al.	Apr 2013	A1
20130101678	Gordon et al.	Apr 2013	A1
20130101963	Sun	Apr 2013	A1
20130102548	Riley et al.	Apr 2013	A1
20130102679	Holden	Apr 2013	A1
20130108708	Xu	May 2013	A1
20130110162	Cohen	May 2013	A1
20130116323	Tirouvanziam et al.	May 2013	A1
20130123225	Melander et al.	May 2013	A1
20130123319	Bryan	May 2013	A1
20130129768	Reynolds	May 2013	A1
20130129795	Melander et al.	May 2013	A1
20130129800	Giammona et al.	May 2013	A1
20130131172	Zhang et al.	May 2013	A1
20130131575	Dacey, Jr. et al.	May 2013	A1
20130136730	Frank et al.	May 2013	A1
20130136782	Blackwell et al.	May 2013	A1
20130149345	Lipp et al.	Jun 2013	A1
20130149542	Chen et al.	Jun 2013	A1
20130150451	Salamone et al.	Jun 2013	A1
20130150809	Whiteford et al.	Jun 2013	A1
20130158127	Sergere	Jun 2013	A1
20130158488	Weaver et al.	Jun 2013	A1
20130158517	Bouchard et al.	Jun 2013	A1
20130158518	Li et al.	Jun 2013	A1
20130164228	Jaracz et al.	Jun 2013	A1
20130164338	Lipp et al.	Jun 2013	A1
20130164363	Raad	Jun 2013	A1
20130164736	Bernardi et al.	Jun 2013	A1
20130165595	Reid et al.	Jun 2013	A1
20130171210	Baker	Jul 2013	A1
20130171224	Percival et al.	Jul 2013	A1
20130171228	Morris	Jul 2013	A1
20130172187	Melander et al.	Jul 2013	A1
20130183435	Sun et al.	Jul 2013	A1
20130190699	Stephan	Jul 2013	A1
20130196365	Reddy et al.	Aug 2013	A1
20130197455	Zhang	Aug 2013	A1
20130210708	Singh et al.	Aug 2013	A1
20130213398	Lipp et al.	Aug 2013	A1
20130220331	Yahiaoui et al.	Aug 2013	A1
20130224112	Boyden et al.	Aug 2013	A1
20130224258	Baker	Aug 2013	A1
20130224260	Ward et al.	Aug 2013	A1
20130225675	Kubala et al.	Aug 2013	A1
20130231302	Raad et al.	Sep 2013	A1
20130243828	Lipp et al.	Sep 2013	A1
20130245116	Takayama et al.	Sep 2013	A1
20130245130	Watnick et al.	Sep 2013	A1
20130252815	Kolter et al.	Sep 2013	A1
20130252818	Lovejoy et al.	Sep 2013	A1
20130252945	Lovejoy et al.	Sep 2013	A1
20130266521	Fetissova et al.	Oct 2013	A1
20130266522	Fagon et al.	Oct 2013	A1
20130266629	Son	Oct 2013	A1
20130266653	Lipp et al.	Oct 2013	A1
20130267471	Ghatnekar et al.	Oct 2013	A1
20130273116	Jespersen et al.	Oct 2013	A1
20130281324	Gouliaev et al.	Oct 2013	A1
20130281503	Melander et al.	Oct 2013	A1
20130287860	Tennican et al.	Oct 2013	A1
20130287861	Tennican et al.	Oct 2013	A1
20130288951	Troxel et al.	Oct 2013	A1
20130302390	Davies	Nov 2013	A1
20130309219	Ratner et al.	Nov 2013	A1
20130310346	Zurawski	Nov 2013	A1
20130315874	Melander et al.	Nov 2013	A1
20130315967	Bruno	Nov 2013	A1
20130315972	Krasnow et al.	Nov 2013	A1
20130330386	Whitten et al.	Dec 2013	A1
20130330388	Sekhar	Dec 2013	A1
20130337088	Widgerow	Dec 2013	A1
20130344542	Cascao-Pereira et al.	Dec 2013	A1
20130345261	Waters et al.	Dec 2013	A1
20140005605	Samade et al.	Jan 2014	A1
20140020138	Ragunath et al.	Jan 2014	A1
20140023691	Melander et al.	Jan 2014	A1
20140030306	Polizzotti et al.	Jan 2014	A1
20140037688	Berkes et al.	Feb 2014	A1
20140037967	Roth et al.	Feb 2014	A1
20140039195	Luk et al.	Feb 2014	A1
20140039357	Boyden et al.	Feb 2014	A1
20140045213	Otto et al.	Feb 2014	A1
20140056951	Losick et al.	Feb 2014	A1
20140056952	Losick et al.	Feb 2014	A1
20140056993	Parsons	Feb 2014	A1
20140057324	Aehle et al.	Feb 2014	A1
20140065200	Schoenfisch et al.	Mar 2014	A1
20140066441	Surber et al.	Mar 2014	A1
20140072525	Adams, Jr. et al.	Mar 2014	A1
20140073560	Shanks et al.	Mar 2014	A1
20140073690	Meijler et al.	Mar 2014	A1
20140079741	Bink et al.	Mar 2014	A1
20140079808	Melander et al.	Mar 2014	A1
20140083324	Wales et al.	Mar 2014	A1
20140105986	Doxey et al.	Apr 2014	A1
20140107071	Kougoulos et al.	Apr 2014	A1
20140120052	Hen et al.	May 2014	A1
20140127273	Melander et al.	May 2014	A1
20140128313	Bishop et al.	May 2014	A1
20140128590	Bornscheuer et al.	May 2014	A1
20140142028	Eckert et al.	May 2014	A1
20140142107	Kaufman et al.	May 2014	A1
20140147481	Gerwick et al.	May 2014	A1
20140155318	Zlotkin	Jun 2014	A1
20140155478	Seneviratne et al.	Jun 2014	A1
20140161728	Bowler et al.	Jun 2014	A1
20140161772	Collins et al.	Jun 2014	A1
20140161845	Demuth et al.	Jun 2014	A1
20140170195	Fassih et al.	Jun 2014	A1
20140170238	Cliff et al.	Jun 2014	A1
20140171438	Pan et al.	Jun 2014	A1
20140172049	Nayfach-Battilana	Jun 2014	A1
20140172117	Anzai et al.	Jun 2014	A1
20140178444	Stadler et al.	Jun 2014	A1
20140186318	Ghannoum et al.	Jul 2014	A1
20140186409	Lang et al.	Jul 2014	A1
20140187666	Aizenberg et al.	Jul 2014	A1
20140193489	Rahimipour et al.	Jul 2014	A1
20140193866	Lam et al.	Jul 2014	A1
20140193889	McDaniel	Jul 2014	A1
20140194594	Gorr	Jul 2014	A1
20140200511	Boyden et al.	Jul 2014	A1
20140205586	Xi et al.	Jul 2014	A1
20140205643	Onsoyen et al.	Jul 2014	A1
20140212828	Falcone et al.	Jul 2014	A1
20140221331	Barraud et al.	Aug 2014	A1
20140221610	Zlotkin	Aug 2014	A1
20140223602	Chang et al.	Aug 2014	A1
20140228327	Raad	Aug 2014	A1
20140234380	Rayad et al.	Aug 2014	A1
20140241997	McInroy et al.	Aug 2014	A1
20140242023	Doxey et al.	Aug 2014	A1
20140243725	Tennican et al.	Aug 2014	A1
20140248373	Michalow et al.	Sep 2014	A1
20140255318	Stasko et al.	Sep 2014	A1
20140256812	Zhang et al.	Sep 2014	A1
20140257482	Ward et al.	Sep 2014	A1
20140271757	Agrawal et al.	Sep 2014	A1
20140271763	Burzell	Sep 2014	A1
20140271777	Quave et al.	Sep 2014	A1
20140274875	Troxel et al.	Sep 2014	A1
20140276253	Varga et al.	Sep 2014	A1
20140276254	Varga et al.	Sep 2014	A1
20140277301	Varga et al.	Sep 2014	A1
20140288007	Dashper et al.	Sep 2014	A1
20140288171	Whang et al.	Sep 2014	A1
20140294907	Bruno	Oct 2014	A1
20140295523	Steer et al.	Oct 2014	A1
20140302113	Zhang	Oct 2014	A1
20140308217	Schaeffer-Korbylo et al.	Oct 2014	A1
20140308317	Fan et al.	Oct 2014	A1
20140308361	Rayad et al.	Oct 2014	A1
20140322351	Gawande et al.	Oct 2014	A1
20140322362	Frim et al.	Oct 2014	A1
20140328887	Olson et al.	Nov 2014	A1
20140328890	Olson et al.	Nov 2014	A1
20140328895	Friedman et al.	Nov 2014	A1
20140328999	Aizenberg et al.	Nov 2014	A1
20140335144	Ward et al.	Nov 2014	A1
20140336159	Clarke et al.	Nov 2014	A1
20140336700	Dave et al.	Nov 2014	A1
20140342954	Ingber et al.	Nov 2014	A1
20140348780	Glasnapp	Nov 2014	A1
20140349917	Eckert et al.	Nov 2014	A1
20140350017	Williams et al.	Nov 2014	A1
20140357592	O'Neil et al.	Dec 2014	A1
20140370078	Gurtner et al.	Dec 2014	A1
20140371171	Souweine	Dec 2014	A1
20140371476	Dayton et al.	Dec 2014	A1
20140377826	Trevethick	Dec 2014	A1
20150004233	Lipp et al.	Jan 2015	A1
20150005228	Yang et al.	Jan 2015	A1
20150011504	Gong et al.	Jan 2015	A1
20150018284	Ghatnekar	Jan 2015	A1
20150018330	Hoffman et al.	Jan 2015	A1
20150024000	Shirtliff et al.	Jan 2015	A1
20150024017	Bukshpan et al.	Jan 2015	A1
20150024052	Doxey	Jan 2015	A1
20150031738	Li et al.	Jan 2015	A1
20150038512	Looper et al.	Feb 2015	A1
20150038705	Williams et al.	Feb 2015	A1
20150044147	Rayad et al.	Feb 2015	A1
20150044260	Birkedal et al.	Feb 2015	A1
20150044266	Fetissova et al.	Feb 2015	A1
20150045515	Li et al.	Feb 2015	A1
20150050717	Collins et al.	Feb 2015	A1
20150056411	Zhang et al.	Feb 2015	A1
20150072066	Karandikar et al.	Mar 2015	A1
20150079141	Wingfield	Mar 2015	A1
20150080289	Yang et al.	Mar 2015	A1
20150080290	Bevilacqua et al.	Mar 2015	A1
20150086561	Kauvar et al.	Mar 2015	A1
20150086631	Kishen et al.	Mar 2015	A1
20150087573	Estell et al.	Mar 2015	A1
20150087582	LoVetri et al.	Mar 2015	A1
20150094368	Scholz et al.	Apr 2015	A1
20150099020	Genin	Apr 2015	A1
20150110898	Gordon et al.	Apr 2015	A1
20150111813	Schuch et al.	Apr 2015	A1
20150114504	Cecka et al.	Apr 2015	A1
20150118219	Shi et al.	Apr 2015	A1
20150132352	Sun et al.	May 2015	A1
20150136130	DeHaan et al.	May 2015	A1
20150147372	Agrawal et al.	May 2015	A1
20150147775	Fiacco et al.	May 2015	A1
20150148286	Hakansson et al.	May 2015	A1
20150148612	Schaeffer et al.	May 2015	A1
20150157542	Schaeffer-Korbylo et al.	Jun 2015	A1
20150157720	Folan	Jun 2015	A1
20150159180	Prabhune et al.	Jun 2015	A1
20150164769	Mello et al.	Jun 2015	A1
20150165095	Mansouri et al.	Jun 2015	A1
20150166706	Hrabie et al.	Jun 2015	A1
20150166796	Sun et al.	Jun 2015	A1
20150167046	Ramasubramanian et al.	Jun 2015	A1
20150173883	Ingber et al.	Jun 2015	A1
20150174302	Troxel et al.	Jun 2015	A1
20150182667	Guelcher et al.	Jul 2015	A1
20150183746	Melander et al.	Jul 2015	A1
20150190447	Luc et al.	Jul 2015	A1
20150191607	McDaniel	Jul 2015	A1
20150197538	Janetka et al.	Jul 2015	A1
20150197558	Kauvar et al.	Jul 2015	A1
20150202227	Lipp et al.	Jul 2015	A1
20150209393	Chang et al.	Jul 2015	A1
20150224220	Olson et al.	Aug 2015	A1
20150225458	Rapsch et al.	Aug 2015	A1
20150225488	Schoenfisch et al.	Aug 2015	A1
20150231045	Krohn et al.	Aug 2015	A1
20150231066	Lipp et al.	Aug 2015	A1
20150231287	Lin et al.	Aug 2015	A1
20150237870	Pei	Aug 2015	A1
20150238543	Rickard et al.	Aug 2015	A1
20150245618	Agrawal et al.	Sep 2015	A9
20150246995	Hanson et al.	Sep 2015	A1
20150250875	Lipp et al.	Sep 2015	A1
20150259390	Zlotkin	Sep 2015	A1
20150267162	Kanehara et al.	Sep 2015	A1
20150274639	Williams et al.	Oct 2015	A1
20150283208	Ribbeck et al.	Oct 2015	A1
20150283287	Agarwal et al.	Oct 2015	A1
20150297478	Ratcliff et al.	Oct 2015	A1
20150297642	Borody	Oct 2015	A1
20150299298	Kauvar et al.	Oct 2015	A1
20150299345	Xu et al.	Oct 2015	A1
20150315253	Zlotkin et al.	Nov 2015	A1
20150322113	Atreya et al.	Nov 2015	A1
20150322272	Pokroy et al.	Nov 2015	A1
20150327552	Melander et al.	Nov 2015	A1
20150330020	van Buskirk et al.	Nov 2015	A1
20150332151	Marculescu et al.	Nov 2015	A1
20150335013	Sabin	Nov 2015	A1
20150335027	Sabin	Nov 2015	A1
20150336855	Sabin	Nov 2015	A1
20150344918	Lam et al.	Dec 2015	A1
20150351383	Kolari et al.	Dec 2015	A1
20150351392	Graber et al.	Dec 2015	A1
20150351406	Wingfield et al.	Dec 2015	A1
20150368480	Reches	Dec 2015	A1
20150373989	Krasnow et al.	Dec 2015	A1
20150374634	Koo et al.	Dec 2015	A1
20150374658	Krohn et al.	Dec 2015	A1
20150374720	Genberg et al.	Dec 2015	A1
20160008275	Doxey et al.	Jan 2016	A1
20160009733	Barraud et al.	Jan 2016	A1
20160010137	Potnis et al.	Jan 2016	A1
20160015047	Gawande et al.	Jan 2016	A1
20160021882	Wang et al.	Jan 2016	A1
20160022564	Townsend et al.	Jan 2016	A1
20160022595	Shikani et al.	Jan 2016	A1
20160022707	Zhong et al.	Jan 2016	A1
20160024551	Hassett et al.	Jan 2016	A1
20160030327	Stein	Feb 2016	A1
20160031941	Eckert et al.	Feb 2016	A1
20160032180	Agrawal et al.	Feb 2016	A1
20160038572	Nelson	Feb 2016	A1
20160038650	Griffith	Feb 2016	A1
20160045841	Kaplan et al.	Feb 2016	A1
20160051569	Banov	Feb 2016	A1
20160058675	Xu et al.	Mar 2016	A1
20160058693	Widgerow	Mar 2016	A1
20160058772	Baker	Mar 2016	A1
20160058816	Widgerow	Mar 2016	A1
20160058834	Ghatnekar	Mar 2016	A1
20160058998	Skiba et al.	Mar 2016	A1
20160060284	Oscarson et al.	Mar 2016	A1
20160060609	Bornscheuer et al.	Mar 2016	A1
20160067149	Kishen	Mar 2016	A1
20160073638	Li et al.	Mar 2016	A1
20160074345	Holden	Mar 2016	A1
20160075714	Opperman et al.	Mar 2016	A1
20160075749	Nibbering et al.	Mar 2016	A1
20160089481	Arvidsson et al.	Mar 2016	A1
20160096865	Martinez et al.	Apr 2016	A1
20160106107	Marques et al.	Apr 2016	A1
20160106689	O'Neil	Apr 2016	A1
20160107126	Cates	Apr 2016	A1
20160109401	Wardell et al.	Apr 2016	A1
20160113940	Crapo et al.	Apr 2016	A1
20160115145	Kolter et al.	Apr 2016	A1
20160120184	Gedanken et al.	May 2016	A1
20160120793	Abdalla et al.	May 2016	A1
20160122697	Skiba et al.	May 2016	A1
20160128335	Sabin	May 2016	A1
20160129078	Ko et al.	May 2016	A1
20160135463	Reid et al.	May 2016	A9
20160135469	Olson et al.	May 2016	A1
20160135470	Agrawal et al.	May 2016	A1
20160137563	Sabin	May 2016	A1
20160137564	Sabin	May 2016	A1
20160137565	Sabin	May 2016	A1
20160144004	Pellico	May 2016	A1
20160145289	Janetka et al.	May 2016	A1
20160157497	Zlotkin	Jun 2016	A1
20160158169	O'Neil et al.	Jun 2016	A1
20160158353	Kielian	Jun 2016	A1
20160158421	Troxel et al.	Jun 2016	A1
20160166712	Pavlicek et al.	Jun 2016	A1
20160168604	Lam et al.	Jun 2016	A1
20160176815	Li et al.	Jun 2016	A1
20160184485	Zhang	Jun 2016	A1
20160185630	Gupta et al.	Jun 2016	A1
20160186147	Cady et al.	Jun 2016	A1
20160193344	Sershen et al.	Jul 2016	A1
20160194288	Melander et al.	Jul 2016	A1
20160198994	Murphy et al.	Jul 2016	A1
20160199295	Doxey et al.	Jul 2016	A1
20160205946	Staueeer et al.	Jul 2016	A1
20160206575	O'Neil et al.	Jul 2016	A1
20160212996	Ghigo et al.	Jul 2016	A1
20160213001	Parthasarathy et al.	Jul 2016	A1
20160220722	Wardell et al.	Aug 2016	A1
20160220728	Adams et al.	Aug 2016	A1
20160223553	Sears et al.	Aug 2016	A1
20160235698	Rickard et al.	Aug 2016	A1
20160235893	Lucchino et al.	Aug 2016	A1
20160235894	Ghigo et al.	Aug 2016	A1
20160237145	Kauvar et al.	Aug 2016	A1
20160242413	Wuest et al.	Aug 2016	A1
20160249612	Gambogi et al.	Sep 2016	A1
20160251571	Agrawal et al.	Sep 2016	A1
20160256484	Doxey et al.	Sep 2016	A1
20160262384	Wuest et al.	Sep 2016	A1
20160263225	Zakrewsky et al.	Sep 2016	A1
20160270411	Mart Nore et al.	Sep 2016	A1
20160278375	Wuest et al.	Sep 2016	A1
20160279138	Surber et al.	Sep 2016	A1
20160279191	Glasnapp	Sep 2016	A1
20160279314	Eliaz	Sep 2016	A1
20160280570	Fratt et al.	Sep 2016	A1
20160280772	Salomon et al.	Sep 2016	A1
20160289272	Otterlei et al.	Oct 2016	A1
20160289287	Hancock et al.	Oct 2016	A1
20160296434	Fei et al.	Oct 2016	A1
20160304886	Rickard et al.	Oct 2016	A1
20160309711	Jackson et al.	Oct 2016	A1
20160317611	Nibbering et al.	Nov 2016	A1
20160317618	Fikrig et al.	Nov 2016	A1
20160319224	Lant et al.	Nov 2016	A1
20160319225	Lant et al.	Nov 2016	A1
20160319226	Lant et al.	Nov 2016	A1
20160319227	Lant et al.	Nov 2016	A1
20160319228	Lant et al.	Nov 2016	A1
20160324531	Gross et al.	Nov 2016	A1
20160326503	Barton et al.	Nov 2016	A1
20160330962	Looper et al.	Nov 2016	A1
20160331719	Watnick et al.	Nov 2016	A1
20160338993	Martins-Green et al.	Nov 2016	A1
20160339071	Tufenkji et al.	Nov 2016	A1
20160346115	Varga et al.	Dec 2016	A1
20160346161	Varga et al.	Dec 2016	A1
20160346294	Sengupta et al.	Dec 2016	A1
20160346436	Boluk et al.	Dec 2016	A1
20160353739	Melander et al.	Dec 2016	A1
20160353746	Dale et al.	Dec 2016	A1
20160354289	Sternoff et al.	Dec 2016	A1
20160355487	Huigens et al.	Dec 2016	A1
20160375034	Baker et al.	Dec 2016	A1
20160375074	Quave et al.	Dec 2016	A1
20160376449	Reches	Dec 2016	A1
20170007733	Boyden et al.	Jan 2017	A1
20170009084	Margel et al.	Jan 2017	A1
20170014208	Falcone et al.	Jan 2017	A1
20170014437	Luk et al.	Jan 2017	A1
20170014511	Vitaliano et al.	Jan 2017	A1
20170020139	Berkes et al.	Jan 2017	A1
20170020813	Lipp et al.	Jan 2017	A1
20170021040	Vitaliano et al.	Jan 2017	A1
20170022165	Lu et al.	Jan 2017	A1
20170022371	Lynn et al.	Jan 2017	A1
20170028106	Brisbois et al.	Feb 2017	A1
20170029363	Caran et al.	Feb 2017	A1
20170035786	Banov	Feb 2017	A1
20170035955	Eliaz	Feb 2017	A1
20170042965	Bevilacqua et al.	Feb 2017	A1
20170043111	Hoftman et al.	Feb 2017	A1
20170044222	Alexander et al.	Feb 2017	A1
20170049113	Duncan et al.	Feb 2017	A1
20170050893	Sabin	Feb 2017	A1
20170050927	Li et al.	Feb 2017	A1
20170056297	Kishen et al.	Mar 2017	A1
20170056405	Sun et al.	Mar 2017	A1
20170056437	Stasko et al.	Mar 2017	A1
20170056454	Berkes et al.	Mar 2017	A1
20170056455	Berkes et al.	Mar 2017	A1
20170056565	Kepler et al.	Mar 2017	A1
20170064966	Opatowsky et al.	Mar 2017	A1
20170065564	Shaw et al.	Mar 2017	A1
20170065673	Birkedal et al.	Mar 2017	A1
20170071212	Sabin	Mar 2017	A1
20170071986	Kovarik et al.	Mar 2017	A1
20170072024	Malepeyre et al.	Mar 2017	A1
20170072098	Drago et al.	Mar 2017	A1
20170073706	Ghigo et al.	Mar 2017	A1
20170080130	Pichler-Wilhelm et al.	Mar 2017	A1
20170095502	Sarangapani	Apr 2017	A1
20170100328	Kovarik et al.	Apr 2017	A1
20170100348	Wright	Apr 2017	A1
20170100357	Folan	Apr 2017	A1
20170100512	Matheny	Apr 2017	A1
20170100513	Matheny	Apr 2017	A1
20170100514	Matheny	Apr 2017	A1
20170100515	Matheny	Apr 2017	A1
20170100516	Matheny	Apr 2017	A1
20170100517	Matheny	Apr 2017	A1
20170100518	Matheny	Apr 2017	A1
20170100522	Matheny	Apr 2017	A1
20170100523	Matheny	Apr 2017	A1
20170106188	King et al.	Apr 2017	A1
20170107250	Stensen et al.	Apr 2017	A1
20170112136	Wood et al.	Apr 2017	A1
20170112723	Xu et al.	Apr 2017	A1
20170113038	Nagel et al.	Apr 2017	A1
20170119915	Lin et al.	May 2017	A1
20170127683	Schuch et al.	May 2017	A1
20170128338	Gawande et al.	May 2017	A1
20170128502	Berkes et al.	May 2017	A1
20170128720	Skiba	May 2017	A1
20170135342	Caran et al.	May 2017	A1
20170137380	Rodrigues et al.	May 2017	A1
20170142978	Falken	May 2017	A1
20170143624	Lipp et al.	May 2017	A1
20170143842	Smyth et al.	May 2017	A1
20170150724	Baker	Jun 2017	A1
20170156321	Li et al.	Jun 2017	A1
20170158537	Buschmann	Jun 2017	A1
20170158727	Coenye et al.	Jun 2017	A1
20170159237	Buschmann et al.	Jun 2017	A1
20170173186	Pavlicek et al.	Jun 2017	A9
20170173225	Troxel	Jun 2017	A1
20170182205	Zupancic et al.	Jun 2017	A1
20170183469	Falken et al.	Jun 2017	A1
20170189556	Seleem	Jul 2017	A1
20170197028	Goldsmith	Jul 2017	A1
20170202752	Xu et al.	Jul 2017	A1
20170204123	Holmes et al.	Jul 2017	A1
20170216094	Reo et al.	Aug 2017	A1
20170216197	McHale et al.	Aug 2017	A1
20170216369	Sabacinski et al.	Aug 2017	A1
20170216377	Berkes et al.	Aug 2017	A1
20170216410	Howell et al.	Aug 2017	A1
20170224703	Kaufman et al.	Aug 2017	A1
20170224748	Berkes et al.	Aug 2017	A1
20170226133	Holmes et al.	Aug 2017	A1
20170232038	O'Flaherty et al.	Aug 2017	A1
20170232048	Edwards	Aug 2017	A1
20170232153	Babu et al.	Aug 2017	A1
20170240618	Zurawski	Aug 2017	A1
20170246205	Stasko et al.	Aug 2017	A1
20170246341	Hanson et al.	Aug 2017	A1
20170247401	Janetka et al.	Aug 2017	A1
20170247409	Moreira et al.	Aug 2017	A1
20170247414	Gruber	Aug 2017	A1
20170247688	Franch et al.	Aug 2017	A1
20170252320	Martins-Green et al.	Sep 2017	A1
20170258963	Savage et al.	Sep 2017	A1
20170266239	Borody	Sep 2017	A1
20170266306	Eckert et al.	Sep 2017	A1
20170273301	Benson	Sep 2017	A1
20170274082	Sershen et al.	Sep 2017	A1
20170280725	Jin et al.	Oct 2017	A1
20170281570	Gurtner et al.	Oct 2017	A1
20170281667	Acharya et al.	Oct 2017	A1
20170281699	Berkes et al.	Oct 2017	A1
20170283763	Newman et al.	Oct 2017	A1
20170290789	DiCosmo	Oct 2017	A1
20170290854	Matlick	Oct 2017	A1
20170295784	Bolduc et al.	Oct 2017	A1
20170296599	Berkes et al.	Oct 2017	A1
20170297055	Detrembleur et al.	Oct 2017	A1
20170304564	DeHaan et al.	Oct 2017	A1
20170312307	Stasko et al.	Nov 2017	A1
20170312345	Ivanova et al.	Nov 2017	A1
20170326054	Spears et al.	Nov 2017	A1
20170333455	Manley et al.	Nov 2017	A1
20170333601	Burgess et al.	Nov 2017	A1
20170339962	Sabin	Nov 2017	A1
20170340779	Burgess et al.	Nov 2017	A1
20170347661	Parsons	Dec 2017	A1
20170347664	Thompson et al.	Dec 2017	A1
20170360534	Sun et al.	Dec 2017	A1
20170360982	Wardell et al.	Dec 2017	A1
20170362562	Nguyen et al.	Dec 2017	A1
20170367933	Aparicio et al.	Dec 2017	A1
20180000993	Zhang	Jan 2018	A1
20180008533	McHale et al.	Jan 2018	A1
20180008742	Hoggarth et al.	Jan 2018	A1
20180014974	Hoggarth et al.	Jan 2018	A1
20180014975	Hoggarth et al.	Jan 2018	A1
20180015061	Gawande et al.	Jan 2018	A1
20180016311	Zlotkin et al.	Jan 2018	A1
20180021463	Osinski et al.	Jan 2018	A1
20180028417	Koo et al.	Feb 2018	A1
20180028701	Fu et al.	Feb 2018	A1
20180028713	Agarwal et al.	Feb 2018	A1
20180030403	Subhadra	Feb 2018	A1
20180030404	Subhadra	Feb 2018	A1
20180030405	Subhadra	Feb 2018	A1
20180030406	Subhadra	Feb 2018	A1
20180036286	Shaw et al.	Feb 2018	A1
20180036702	Wellings	Feb 2018	A1
20180037545	Silver	Feb 2018	A1
20180037613	Paetzold et al.	Feb 2018	A1
20180042789	Bradford et al.	Feb 2018	A1
20180042928	Sun et al.	Feb 2018	A1
20180043190	Myers et al.	Feb 2018	A1
20180049856	Ionescu et al.	Feb 2018	A1
20180051061	Wang	Feb 2018	A1
20180079757	Tse-Dinh et al.	Mar 2018	A1
20180079912	Reches	Mar 2018	A1
20180085335	Sun et al.	Mar 2018	A1
20180085392	Gaspar et al.	Mar 2018	A1
20180085489	Hanson et al.	Mar 2018	A1
20180085717	Ermatov et al.	Mar 2018	A1
20180092939	Onsoyen et al.	Apr 2018	A1
20180093011	Kellar et al.	Apr 2018	A1
20180094214	Labib et al.	Apr 2018	A1
20180105792	Subhadra	Apr 2018	A1
20180110228	Myers et al.	Apr 2018	A1
20180111893	Wuest et al.	Apr 2018	A1
20180111955	Oscarson et al.	Apr 2018	A1
20180112068	Segal et al.	Apr 2018	A1
20180119235	Talianski et al.	May 2018	A1
20180125066	Bassler et al.	May 2018	A1
20180125070	Looper et al.	May 2018	A1
20180133326	McInroy et al.	May 2018	A1
20180153172	Zlotkin	Jun 2018	A1
20180153996	Lipp et al.	Jun 2018	A1
20180184656	DiLuccio	Jul 2018	A1
20180185518	Vitaliano et al.	Jul 2018	A1
20180194792	Janetka et al.	Jul 2018	A1
20180200185	Labib et al.	Jul 2018	A1
20180207122	Scholz et al.	Jul 2018	A1
20180244901	Kenny et al.	Aug 2018	A1
20180265475	Huigens et al.	Sep 2018	A1
20180298307	Lant et al.	Oct 2018	A1
20180298552	van Buskirk et al.	Oct 2018	A9
20180303846	Domenico	Oct 2018	A1
20180310566	Sawyer et al.	Nov 2018	A1
20180312473	Huigens	Nov 2018	A1
20180318313	Sengupta et al.	Nov 2018	A1
20180325740	Kenny et al.	Nov 2018	A1
20180338945	Sambasivam	Nov 2018	A1
20180353556	Berkes et al.	Dec 2018	A1
20180360856	Holmes et al.	Dec 2018	A1
20180369258	Holmes et al.	Dec 2018	A1
20190000090	Wood et al.	Jan 2019	A1
20190002706	Margel et al.	Jan 2019	A1
20190003113	Altman et al.	Jan 2019	A1
20190008784	Jacks et al.	Jan 2019	A1
20190017050	Thanos et al.	Jan 2019	A1
20190031545	Buschmann et al.	Jan 2019	A1
20190048308	Nguyen et al.	Feb 2019	A1
20190099459	Camilli et al.	Apr 2019	A1
20190125825	Blackledge et al.	May 2019	A1
20190134151	Bond et al.	May 2019	A1
20190144738	Agrawal et al.	May 2019	A1
20190192691	Barrett et al.	Jun 2019	A1
20190201371	Baker	Jul 2019	A1
20190209646	Xie	Jul 2019	A1
20190211045	Janetka et al.	Jul 2019	A1
20190211312	Cady et al.	Jul 2019	A1
20190216691	Wellings	Jul 2019	A1
20190249115	Labib et al.	Aug 2019	A1
20190262393	Pesavento	Aug 2019	A1
20190264164	Nguyen et al.	Aug 2019	A1
20190282754	Koulakis et al.	Sep 2019	A1
20190307726	Holmgren et al.	Oct 2019	A1
20190322988	Cady et al.	Oct 2019	A1
20190330618	Franch et al.	Oct 2019	A1
20190352592	Nguyen et al.	Nov 2019	A1
20190365868	Sauer et al.	Dec 2019	A1
20190373890	Huigens et al.	Dec 2019	A1
20190374213	Goldsmith	Dec 2019	A1
20190376052	Steer et al.	Dec 2019	A1
20190381038	Altschul et al.	Dec 2019	A1
20190381057	Surber et al.	Dec 2019	A1
20190387745	Schuch et al.	Dec 2019	A1
20190388342	Sung et al.	Dec 2019	A1
20200002377	Van Den Nest et al.	Jan 2020	A1
20200010432	Huigens et al.	Jan 2020	A1
20200022989	Baker	Jan 2020	A1
20200031757	Looper et al.	Jan 2020	A1
20200069777	Staples et al.	Mar 2020	A1
20200071702	Thanos et al.	Mar 2020	A1
20200102340	Oscarson et al.	Apr 2020	A1
20200107551	Sawyer et al.	Apr 2020	A1
20200108107	Berkes et al.	Apr 2020	A1
20200109297	McDaniel	Apr 2020	A1
20200121715	Bishop et al.	Apr 2020	A1
20200138033	Baker	May 2020	A1
20200138037	Dale et al.	May 2020	A1
20200138708	Labib et al.	May 2020	A1
20200138753	Jennings et al.	May 2020	A1
20200154708	Stadler et al.	May 2020	A1
20200155640	Heckler et al.	May 2020	A1
20200163333	Gandhi et al.	May 2020	A1
20200164080	Hedrick et al.	May 2020	A1
20200172853	Nguyen et al.	Jun 2020	A1
20200179458	Ambrogio et al.	Jun 2020	A1
20200197483	Bond et al.	Jun 2020	A1
20200199000	Buschmann	Jun 2020	A1
20200206277	Whitlock et al.	Jul 2020	A1
20200215123	Thanos et al.	Jul 2020	A1
20200216836	Franch et al.	Jul 2020	A1
20200256009	Altman et al.	Aug 2020	A1
20200261667	DeHaan et al.	Aug 2020	A1
20200263123	Nguyen et al.	Aug 2020	A1
20200264050	Auner et al.	Aug 2020	A1
20200268031	Macur et al.	Aug 2020	A1
20200270559	Macur et al.	Aug 2020	A1
20200270613	Thanos et al.	Aug 2020	A1
20200275653	Davies	Sep 2020	A1
20200276214	Waters et al.	Sep 2020	A1
20200277263	Wuest et al.	Sep 2020	A1
20200296971	McLean et al.	Sep 2020	A1
20200299521	McDaniel	Sep 2020	A1
20200306163	Altman	Oct 2020	A1
20200318284	van Buskirk et al.	Oct 2020	A1
20200330206	Sagel et al.	Oct 2020	A1
20200330340	Sagel et al.	Oct 2020	A1
20200330341	Sagel et al.	Oct 2020	A1
20200330510	Chatzistavrou et al.	Oct 2020	A1
20200330784	Sagel et al.	Oct 2020	A1
20200345585	Dresdner, Jr. et al.	Nov 2020	A1
20200353085	Farmer et al.	Nov 2020	A1
20200354588	McDaniel	Nov 2020	A1
20200368312	Heckler et al.	Nov 2020	A1
20200397547	Sagel et al.	Dec 2020	A1
20200397548	Sagel et al.	Dec 2020	A1
20200397549	Sagel et al.	Dec 2020	A1
20200397550	Sagel et al.	Dec 2020	A1
20200399562	Lant et al.	Dec 2020	A1

Foreign Referenced Citations (23)

Number	Date	Country
2310246	Sep 1974	DE
2349090	Apr 1975	DE
06849263	Apr 1975	EP
06849263	Dec 2020	EP
02241546	Apr 1975	JP
07173166	Apr 1975	JP
10182450	Apr 1975	JP
2002241546	Aug 2002	JP
2003137758	May 2003	JP
2004018431	Jan 2004	JP
2006062966	Mar 2006	JP
2007239280	Sep 2007	JP
5495535	Oct 2007	JP
58213716	Oct 2007	JP
59193809	Oct 2007	JP
59199606	Oct 2007	JP
60009728	Oct 2007	JP
61106501	Oct 2007	JP
2007262050	Oct 2007	JP
WO2002027018	Apr 2002	WO
WO2005034933	Apr 2005	WO
WO2007081455	Jul 2007	WO
WO2007092633	Aug 2007	WO

Non-Patent Literature Citations (37)

Entry
Ballatore et al., Carboxylic Acid (Bio)Isosteres in Drug Design, ChemMedChem. Mar. 2013 ; 8(3): 385-395. doi:10.1002/cmdc.201200585. (Year: 2013).
Boon et al., “A Novel DSF-like Signal from Burkholderia cenocepacia Interferes with Candida albicans Morphological Transition,” The ISME Journal 2:27-36 (2008).
Borchardt et al., “Reaction of Acylated Homoserine Lactone Bacterial Signaling Molecules with Oxidized Halogen Antimicrobials,” Appl. Environ. Microbiol. 67(7):3174-3179 (2001).
Davies & Geesey, “Regulation of the Alginate Biosynthesis Gene algC in Pseudomonas aeruginosa During Biofilm Development in Continuous Culture,” Appl. Environ. Microbiol. 61(3):860-7 (1995).
Davies & Marques, “A Fatty Acid Messenger is Responsible for Inducing Dispersion in Microbial Biofilms,” Departnent of Biological Sciences, State University of New York at Binghamtom.
Davies et al., “Exopolysaccharide Production in Biofilms: Substratum Activation of Alginate Gene Expression by Pseudomonas aeruginosa,” Appl. Environ. Microbiol. 59(4):1181-6 (1993).
Davies et al., “The Involvement of Cell-to-Cell Signals in the Development of a Bacterial Biofilm,” Science 280(5361):295-8 (1998).
Davies et al., Abstract Q-100, “Autoinduction of Pseudomonas Aeruginosa Biofilm Dispersion,” ASM 105th General Meeting, Atlanta, GA (Jun. 6, 2005), Biosciences Information Service, XP009133221, Database Accession No. PREV200800237844 (Abstract).
Davies et al., Abstract Q-161, “Autodispersion in Pseudomonas Aeruginosa Biofilms,” ASM 103rd General Meeting, Washington, D.C. (May 20, 2003), Biosciences Information Service, XP009133214, Database Accession No. PREV200300546547 (Abstract).
Dow et al., “Biofilm Dispersal in Xanthomonas campestris is Controlled by Cell-Cell Signaling and is Required for Full Virulence to Plants,” PNAS 100(19):10995-11000 (2003).
Erickson et al., “Pseudomonas aeruginoas Quorum-sensing Systems May Control Virulence Factor Expression in the Lungs of Patients with Cystic Fibrosis,” Infection and Immunity 70(4):1783-1790 (2002).
Extended European Search Report for European Patent Application No. EP06849263 (dated Jun. 10, 2010).
International Search Report dated Nov. 20, 2007.
International Search Report for International Patent Application No. PCT/US08/06171 (dated Aug. 22, 2008).
Irie et al., “Pseudomonas aeruginosa Rhamnolipids Disperse Bordetella bronchiseptica Biofilms,” FEMS Microbiol. Ltrs. 250:237-243 (2005).
Jin et al., “Biofilm-Forming Ability of Candida albicans is Unlikely to Contribute to High Levels of Oral Yeast Carriage in Cases of Human Immunodeficiency Virus Infection,” J. Clin. Microbiol. 41(7):2961-2967 (2003).
Marques et al., “A Fatty Acid Messenger is Responsible for Inducing Dispersion in Microbial Biofilms,” J. Bacteriol. 191(5):1393-1403 (2009).
Marques et al., “Induction of Biofilm Dispersion in Multiple Bacterial Species in Response to a Common Inducer,” American Society for Microbiology (abstract).
Material Safety Data Sheet: Asiatic Acid, Sigma-Aldrich, pp. 1-5 (2010).
McDonnell et al, “Antiseptics and Disinfectants: Activity, Action, and Resistance,” Clinical Microbiology Reviews, vol. 12, No. 1, pp. 147-179 (1999).
McLean et al., “Evidence of Autoinducer Activity in Naturally Occurring Biofilms,” FEMS Microbiol. Ltrs. 154:259-263 (1997).
McLean et al., “Quorum Sensing and Chromobacterium violaceum: Exploitation of Violacein Production and Inhibition for the Detection of N-acylhomoserine Lactones,” Microbiology 143:3703-3711 (1997).
Miller et al., “Quorum Sensing in Bacteria,” Annu. Rev. Microbiol. 55:165-199 (2001).
Mireles et al., “Salmonella enterica Serovar Typhimurium Swarning Mutants with Altered Biofilm-Forming Abilities: Surfactin Inhibits Biofilm Formation,” J. Bacteriol. 183(20):5848-5854 (2001).
Monteiro et al., “Molecular and Structural Characterization of the Biosurfactant Produced by Pseudomonas aeruginosa DAUPE 614,” Chemistry and Physics of Lipids 147:1-13 (2007).
Ramage et al., “Inhibition of Candida Albicans Biofilm Formation by Farnesol, a Quorum-Sensing Molecule,” Applied and Environmental Microbiology 68(11):5459-63 (2002).
Rashid et al., “Polyphosphate Kinase is Essential for Biofilm Development, Quorum Sensing, and Virulence of Pseudomonas aeruginosa,” Proc Nat'l Acad Sci 97(17):9636-41 (2000).
Rice et al., “Biofilm Formation and Sloughing in Serratia marcescens are Controlled by Quorum Sensing and Nutrient Cues,” J. Bacteriol. 187(10):3477-3485 (2005).
Ryan et al., “Diffusible Signals and Interspecies Communication in Bacteria,” Microbiology 154:1845-1858 (2008).
Sauer et al., “Pseudomonas aeruginosa Displays Multiple Phenotypes During Development as a Biofilm,” Journal of Bacteriology 184(4):1140-54 (2002).
Smith et al., “Induction and Inhibition of Pseudomonas aeruginosa Quorum Sensing by Synthetic Autoinducer Analogs,” Chemistry & Biology 10:81-89 (2003).
Stoodley et al., “Biofilms as Complex Differentiated Communities,” Annual Review of Microbiology 56:187-209 (2002).
Tagliente et al., Abstract Q-20, “Development and Dispersion of Pseudomonas Aeruginosa Biofilms,” ASM 101st General Meeting, Orlando, Florida (May 21, 2001), Biosciences Information Service, XP009133213, Database Accession No. PREV200200233614 (Abstract).
Thompson et al., “Chemical Reactions Involved in the Deep-fat Frying of Foods. VII. Identification of Volatile Decomposition Products of Trilinolein,” Journal of the American Oil Chemists' Society 55:897-901 (1978).
Wang et al., “A Bacterial Cell-Cell Communication Signal with Cross-Kingdom Structural Analogues,” Molecular Microbiology, vol. 51, No. 3, pp. 903-912 (2004).
Zhang et al., “Blocking of Candida Albicans Biofilm Formation by Cis-2-Dodecenoic Acid and Trans-2-Dodecenoic Acid,” Journal of Medical Microbiology 60:1643-50 (2011).
Zhang et al., Effect of a Pseudomonas Rhamnolipid Biosurfactant on Cell Hydrophobicity and Biodegradation of Octadecane, Appl. Environ. Microbiol. 60(6):2101-2106 (1994).

Related Publications (1)

	Number	Date	Country
	20200275653 A1	Sep 2020	US

Provisional Applications (2)

	Number	Date	Country
	61018639	Jan 2008	US
	60917791	May 2007	US

Divisions (2)

	Number	Date	Country
Parent	13945207	Jul 2013	US
Child	15931561		US
Parent	12154347	May 2008	US
Child	13945207		US

Induction of a physiological dispersion response in bacterial cells in a biofilm

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

International Classifications

Disclaimer

Abstract